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 Previous studies in our laboratory demonstrated the expression of WT1 in a significant 
number of glioma cells and established its role in promoting tumor cell proliferation. Here, we 
xiv 
 
noted the effect(s) of manipulating WT1 levels on the expression levels of genes that were 
previously shown to be regulated by WT1. We found no correlation between the expression 
levels of WT1 and PDGF-A, Snai1 and E-cadherin and a consistent inverse correlation between 
WT1 and IGF-1R expression in U251-MG cells. To ascertain whether the increased IGF-1R 
levels resulting from WT1 silencing could account for decreased cellular proliferation, we 
utilized siRNA mediated knockdown of IGF-1R and found a modest decrease in cellular 
proliferation instead of an expected increase.  
Gene expression profiling in U251-MG cells was then used to identify candidate target genes for 
WT1. Several genes whose levels directly correlated with WT1 were observed to have putative 
or established oncogenic role(s) in glioma cells or other malignancies. Among the genes that 
correlated inversely, a tumor-suppressor role was attributed to some. Real time RT-PCR helped 
to substantiate these microarray findings in U251-MG cells.  
We also characterized the expression and function of WT1 in U1242-MG and GBM6 cells. 
Interestingly, in these cells WT1 facilitated cell invasiveness but had no discernible influence on 
cellular proliferation. The expressions of the candidate WT1 target genes were also determined 
in these 2 cell lines. At least 3 genes were consistently down-regulated with WT1 silencing in the 
three cell lines- INPP5A, CD97, and TYMS. To determine whether CD97 assisted WT1 in 
facilitating cellular invasion, we silenced CD97 expression using siRNA and noted a significant 
decrease in the cells’ ability to invade through Matrigel-coated filters. We propose that WT1 
xv 
 
profoundly impacts the glioma cells’ invasive ability, and this function is mediated by CD97 
alone or in conjunction with other pro-invasive molecules. 
Our findings argue for the oncogenic role of WT1 in the specific context of glioma cells. They 
also point to a role for the novel pro-invasive protein- CD97- in glioma cells. Further studies are 
necessary to confirm the mechanism by which CD97 promotes invasion as well as to explore its 
potential as a diagnostic and/or therapeutic target.
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Chapter 1: Introduction 
Tumors of the central nervous system (CNS), as with all other organ systems, can be 
either benign or malignant. That is where the similarity ends though, because the consequences 
of even the best-behaved growth in these parts can be extremely morbid, or even fatal, depending 
on its exact location. The utterly non-expansive confines within which the brain and the spinal 
cord are housed, the extreme vulnerability of the neurons to ischemic damage and the risk of 
damage to vital functions entailed in the surgical removal of any tumor lodged in and around the 
organs of the CNS are all factors that set these tumors apart from all others. 
According to the 2007 WHO classification 
[1]
, tumors of the CNS can be broadly 
classified into different categories. These include tumors of the neuroepithelial tissue 
(astrocytomas, oligo-dendroglioma/ -astrocytomas, ependymal tumors and so on), cranial and 
paraspinal nerve tumors (for example. Schwannomas, neurofibromas and so on), tumors of the 
meninges, lymphomas and hematopoietic tumors, sellar tumors, germ cell tumors and the 
metastatic tumors. 
The biological behavior of these tumors can be predicted by grading the neoplasms based 
on their histological appearance. Tumor grading- which is similar across all CNS tumor entities-
also helps determine the appropriate therapeutic approach- especially in deciding whether to 
include or exclude adjuvant radiation and specific chemotherapy protocols
[1]
. 
According to the 2007 WHO classification system, Grade I uniformly refers to tumors 
that have a low proliferative potential and that can be cured by surgical resection alone. 
Neoplasms that are designated Grade II also have low proliferative rates, but possess the ability 
to infiltrate surrounding brain parenchyma. Hence, surgery alone cannot effect a complete cure 
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and Grade II tumors often tend to recur. Such recurrences are usually more aggressive, both in 
their behavior and in their resistance to therapy. Grade III neoplasms differ from the lower 
grades in the high proliferative capacity that the tumor cells possess. There is a significant 
increase in the number of mitotic figures and nuclear atypia seen on microscopic examination of 
these tumor specimens. Patients with Grade III CNS tumors often receive adjuvant radiation and/ 
or chemotherapy. The highest grade of malignancy- Grade IV- is assigned to tumors with a 
rapidly deteriorating course and an inevitably fatal outcome. Microscopically, these tumors are 
associated with a significantly high level of abnormal cells and mitotic figures, and areas of 
necrosis. Examples of Grade IV CNS neoplasms include Glioblastoma Multiforme (GBM), most 
embryonal neoplasms and some sarcomas. Such aggressive tumors are characterized by 
widespread tissue infiltration and a propensity for craniospinal dissemination
[1]
. 
Gliomas (derived from mature glia or their less differentiated precursors) mostly infiltrate 
the surrounding parenchyma diffusely. The WHO classifies these tumors broadly into one of 3 
categories: Astrocytomas, Oligodendrogliomas and Oligoastrocytomas. Differentiating between 
astrocytic and oligodendroglial tumors on histologic examination is somewhat possible by taking 
into account the cell shape, cytoplasmic appearance and the nuclear characteristics
[2]
. 
Astrocytomas are characterized by cells with elongated nuclei which are hyperchromatic and 
irregular. Prominent nucleoli and perinuclear halos are not typical. Some astrocytomas are 
characterized by prominent pink cytoplasm (e.g. gemistocytic or granular cell astrocytoma) 
while others have minimal fibrillary cytoplasm (e.g. fibrillary and small cell astrocytoma) 
[2]
. 
Tumor cells in oligodendrogliomas, on the other hand, have nuclei that are usually round, 
regular and show little inter-cellular pleomorphism. The phenomenon of perinuclear cytoplasmic 
clearing- which gives rise to a “scrambled egg” appearance- although helpful is a rather 
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inconsistent finding
[2]
. Some of the non-specific features that also help to form a diagnosis of 
oligodendroglioma include cortical involvement, microcalcifications, delicate branching 
capillaries and microcysts
[2]
.  
Astrocytomas are the most common primary neoplasms of the CNS from among these 
(Ref: CBTRUS), and also the most intensely studied. The WHO uses the 3-tiered system to 
grade these tumors from Grade II through Grade IV. Based largely on the grading criteria 
established by the St. Anne/ Mayo system, the WHO classification differs from this system only 
in its non-recognition of Grade I gliomas, which are non- infiltrative and lack nuclear atypia, 
mitoses, endothelial proliferation and necrosis and therefore, are associated with a very low 
likelihood of recurrence
[2]
. The characteristic features that help differentiate Grade II through 
Grade IV/ GBM are outlined in the table as shown below: 
Table 1: Features that help differentiate the different grades of gliomas. 
Basis Grade II Grade III/ AA Grade IV/ GBM 
1. Infiltrative capacity + + + 
2. Nuclear atypia & 
pleomorphism 
+ ++ +++ 
3. Mitotic figures + (0-1) ++ (>1) ++(+) 
4. Hyper-cellularity + ++ +++ 
5. Endothelial proliferation - - + 
6. Necrosis - - + 
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Genetic subtypes of GBM based on genomic analysis 
Despite the similar clinical course and histological appearance amongst GBMs, there 
exists a remarkable heterogeneity at the genetic level. The study of the pathogenesis of 
astrocytomas is broadly based on two themes
[3]
- to identify the cell of origin of these tumors (that 
is, whether they arise from de-differentiation of mature astrocytes or from the transformation of 
astrocytic precursor cells) and to uncover the specific genetic abnormalities in different phases or 
grades of these astrocytic neoplasms. While nearly a century’s worth of experiments has not yet 
generated an unequivocal answer to the first question, distinct molecular signaling pathway 
abnormalities have been delineated, that have helped us understand how these tumors progress 
from lower-to higher- grades, or how highly malignant astrocytomas are spontaneously 
generated. In 2009, The Cancer Genome Atlas Network (TCGA) undertook a massive venture, 
studying 206 human GBM samples with respect to their DNA copy number, gene expression, 
DNA methylation, and nucleotide sequence aberrations 
[4]
. These investigations revealed that the 
frequency of somatic alterations, based solely on the copy number data, of the retinoblastoma 
(RB), TP53 and receptor-tyrosine kinase (RTK) pathways was 66%, 70% and 59% respectively 
and these values were greater when sequencing data were taken into account. Moreover, the 
alterations of components within each pathway trended towards statistically significant mutual 
exclusivity. This suggests that deregulation of one component within the pathway diminishes the 
selective pressure for additional ones. However, any one sample was found to have at least one 
aberrant gene from each of the three pathways, and 74% harbored abnormalities involving all 
three pathways. 
The RB pathway: The retinoblastoma protein (pRb) is active in its hypo-phosphorylated state 
[5]
 
and acts to inhibit cell cycle progression through its inhibitive regulatory effect on the E2F 
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family of transcription factors 
[6]
 which have been established to push cells through the G1 phase 
of the cell cycle into the S-phase 
[7]
. Cyclin dependent kinase 4/6 phosphorylates pRb 
[8]
 and 
inactivates it, thereby lifting the hold on cell-cycle progression. The cyclin-dependent kinase 
inhibitor - p16
INK4A
  also known as CDKN2A- binds all available cdk4/6 and causes Cyclin-D1 
to detach from the cdk4/6 complex 
[5]
. Thus unprotected, Cyclin-D undergoes degradation and is 
no longer able to participate in cell cycle regulation 
[5]
.  
As per the TCGA studies 
[4]
, 77% of the 206 samples examined had mutations belonging 
to the Rb pathway, and of these, the most common event was deletion of the 
CDKN2A/CDKN2B locus on chromosome 9p21 (55% and 53%), followed by amplification of 
the CDK4 locus (14%). It was also found that the 9 samples that contained RB1 nucleotide 
substitutions lacked the above-mentioned mutations in the upstream signaling components. 
TP53 pathway: The p53 protein has long been hailed as the “guardian of the genome”, owing to 
its contribution towards maintaining genomic stability 
[9, 10]
 in addition to its myriad other 
extensively documented functions as a tumor suppressor (reviewed in 
[10]
). The p53 protein can 
prevent tumor formation or progression by causing cell-cycle arrest, inhibiting cell growth, 
eliminating the generation of reactive oxygen species (ROS) on account of its antioxidant 
behavior, promoting the removal of permanently damaged cells through death or senescence and 
by promoting apoptosis or autophagy. The exact molecular targets that enable it to influence 
each of these functions are extensively detailed elsewhere 
[10, 11]
. One transcriptional target of 
p53 is the murine double mutant-2 (MDM2) 
[11]
. MDM2, when transcriptionally activated serves 
to inhibit the actions of p53 in two ways 
[11]
- it binds and covers the transactivational domain of 
the latter protein, thereby thwarting its transcriptional activity. Additionally, it also targets p53 
for degradation either by a mechanism involving p300 (which in its turn is inhibited by Arf) or 
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by phosphorylating p53 at its N-terminal end. The CDKN2A locus on chromosome 9p21 
mentioned earlier encodes two different proteins. We have already described briefly, the 
functions of one of these- p
16INK4A
 , which plays an important role in ensuring the functionality of 
pRb. The second product- named ARF (or alternate reading frame) differs from this protein in 
one exon 
[12]
. This protein also serves to stabilize p53 protein by binding MDM2, an event that 
leads to decreased degradation of p53 
[12]
.  
Based on the findings from the TCGA studies 
[4]
, the most common aberrations seen in 
the TP53 signaling pathway included ARF deletions (55%), MDM2 (11%) and MDM4 (4%) 
amplifications, in addition to mutations seen with the p53 gene itself (35%). Previous studies had 
reported that in grades II and III astrocytomas, p53 mutations correlated with an allelic loss of 
17p 
[3]
. Interestingly, loss of heterozygosity (LOH) at 17p was associated with an increase in 
mRNA levels of PDGF-Rα [3], although these studies also showed that the latter abnormality 
could exist without p53 mutations, suggesting that while p53 mutation might be an early event in 
tumor progression, it was not the initial event. Another interesting study 
[13]
 demonstrated that 
the acquisition of p53 mutations correlated with progression of brain tumors from low-grade to 
higher grades, and these mutations were shown to be propagated in a clonal fashion, establishing 
the importance of this “master watchman” protein in halting malignant progression. 
RTK pathway: Receptor tyrosine kinases are cell surface receptors; the ones that are important in 
glial neoplasms include epidermal growth factor receptor (EGFR), platelet-derived growth factor 
receptor (PDGF-R) and fibroblast growth factor receptor (FGF-R). These receptors bind their 
corresponding growth-factor ligands on the extracellular N-terminal side, and are consequently 
activated by a process known as auto-phosphorylation. Phosphorylation of the receptor serves 
two purposes 
[14]
. It results in activation of the intracellular kinase domain, which can then 
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phosphorylate the downstream substrates. Additionally, it creates docking sites for these 
signaling effector molecules involved in transducing the receptor’s signal. These downstream 
effectors of signal transduction are mostly proteins that possess domains (like the SH2 and PTB 
domains) which recognize and bind the phosphorylated tyrosine residues on the activated 
receptor 
[14-16]
. Most of the transducers are proteins with inherent or associated catalytic activity, 
for example- Phosphatidylinositol-3-kinase (PI3-kinase), Phospholipase C- γ (PLC- γ), Src 
family of tyrosine kinases, and the Ras- GTP-ase activating protein (Ras-GAP) among others. 
Other proteins that bind the activated receptor, but are devoid of any catalytic activity are the 
adaptor proteins- such as Grb2, Grb3, Nck, Shc, Crk etc. All these signaling pathway 
components participate in a cascade of reactions that eventually result in cell transformation, 
enhanced survival and proliferative abilities, invasiveness and tumor angiogenesis.  
Studies have proven that the PI3-kinase/AKT (Protein Kinase B) pathway is one of the 
most important ones mediating cellular transformation following receptor tyrosine kinase 
stimulation (reviewed in 17). In fact, it has been established that several growth factor signaling 
pathways converge onto this particular enzyme. The Class I family of PI3-kinases, like the 
others, has two subunits- a p85 regulatory subunit and a p110 catalytic subunit. The enzyme 
binds phosphorylated tyrosine residues via the SH2 domain on the p85 subunit, which leads to 
stimulation of the kinase activity of the p110 catalytic subunit 
[18]
. It is this activation that leads 
to further phosphorylation of the downstream effectors. 
PI3-kinase, which is a lipid kinase, acts upon Phosphatidylinositol-4,5- Bisphosphate 
(PIP2), which is then phosphorylated (and thereby activated) to Phosphatidylinositol- 3,4,5- 
Triphosphate (PIP3). PIP3 now recruits AKT to the cell membrane via its pleckstrin homology 
(PH) domain. Complete AKT phosphorylation is mandatory for its activation. Once that has 
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occurred, active AKT can either act upon cytoplasmic targets or translocate to the nucleus and 
interact with nuclear effectors. One of its many substrates include BAD- a pro-apoptotic protein, 
and the net result is a decrease in its activity. Unopposed action of the anti-apoptotic proteins 
[19]
, 
such as Bcl-2 and Bcl-Xl results in cell survival and consequently, proliferation. 
Tumor suppressor proteins such as neurofibromin 1(NF1) and phosphatase and tensin 
homolog (PTEN) act to keep the proteins that function downstream of RTKs and, therefore, the 
cell’s survival machinery under control. NF1 has a functional Ras-GAP domain and can 
therefore negatively regulate Ras activity 
[17]
. PTEN negatively impacts the PI3K pathway by 
dephosphorylating PIP3 to PIP2 
[17]
, thus blocking the pathway from proceeding further 
downstream.  
In astrocytomas, abnormal functioning of the growth factor receptors can arise in several 
ways- increased expression of ligand with consequently increased frequency of receptor-ligand 
complex formation, increased receptor expression or constitutively activated receptors that 
circumvent the need for ligand binding interactions. Mutations involving the effector molecules 
that lie downstream of the receptors are also common.  
The TCGA studies confirmed previous findings that the variant III deletion of the 
extracellular domain (vIII mutant) and carboxy-terminal deletions with correspondingly altered 
transcripts were the most common EGFR mutations
[4]
. In general, EGFR gene alterations were 
seen in 45% of the cases. Further. 22 out of the 91 GBM specimens studied had focal EGFR 
amplifications, 16 had point mutations and focal amplifications, and 3 cases had only EGFR 
point mutations without amplifications. Other studies have reported frequent over-expression and 
amplification of PGFR-α and β in GBM specimens [3]. FGF-Rs were interesting in their pattern 
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of expression, as studies have shown that while low-grade astrocytomas express FGF-R2, they 
switch to FGF-R1 as they progress to high-grade tumors (reviewed in 3), although the functional 
significance of this was not yet determined. 
The PI3K pathway was found to be dysregulated by activating missense mutations in the 
p110 encoding gene- PI3KCA, resulting in an activated catalytic subunit of PI3K. The 
contribution of NF1 mutations to sporadic GBM has been definitively confirmed by the TCGA’s 
findings of somatic inactivating mutations or deletions of the NF1 gene in at least 47 of the 206 
cases 
[4]
. PTEN mutations frequently involve the phosphatase domains, and germline mutations 
in the NF1 and PTEN genes (resulting in Neurofibromatosis 1 and Cowden disease, respectively) 
each render the individual susceptible to sporadic glioblastoma 
[17]
. 
Based on these gene expression studies analyzing the molecular make-up across hundreds of 
GBM tumor specimens, 4 different classes are known, each of which has a predominant pattern 
of abnormal genetic alteration(s) 
[20]
. These four classes and their accompanying abnormal 
genetic markers are as follows: 
1. Classical subtype: Chromosome 7 amplification and chromosome 10 loss are seen in 
100% of tumors belonging to this sub-type with high level EGFR amplification seen in 
97% of the Classical sub-type. Over 50% of the tumor samples belonging to this sub-type 
demonstrated point or vIII mutations in EGFR. Along with the EGFR amplification, p53 
mutations were found lacking. Neural precursor and stem cell marker, nestin (NES), as 
also Notch and Sonic Hedgehog (SHH) pathways were found to be highly up-regulated in 
these specimens.  
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2. Mesenchymal subtype: Tumor samples belonging to this sub-type displayed a high 
frequency of mutations of the NF-1 gene. They were also found to display a combination 
of increased activity of mesenchymal and astrocytic markers- CD44 and c-mer proto-
oncogene tyrosine kinase (MERTK) - suggestive of the process of epithelial-
mesenchymal transition (EMT) which has been associated with trans-differentiated and 
de-differentiated tumors. 
3. Proneural subtype: Tumors belonging to this sub-type are characterized by alterations of 
PDGFRA and point mutations in isocitrate dehydrogenase 1 (IDH-1) 
[20, 21]
. PDGFRA 
alterations take the form of focal amplification as well as high levels of PDGFRA 
expression. TP53 mutations and loss of heterozygosity (LOH) were also seen to occur 
frequently in these tumors, while chromosome 7 amplification and chromosome 10 loss 
were infrequent events. This group of tumors also demonstrates an up-regulation of genes 
that are involved in oligodendrocytic development such as oligodendrocyte transcription 
factor 2 (OLIG2), PDGFRA and NK2 transcription factor (NKX2-2). High levels of 
OLIG2 have been shown to down-regulate the tumor suppressor p21, a finding that is 
confirmed in proneural tumors.  
4. Neural subtype: Expression of neuronal markers like neurofilament, light polypeptide 
(NEFL), gamma-aminobutyric acid (GABA) A receptor (GABRA1), synaptogamin 1 
(SYT1) and solute carrier family 12 (potassium/chloride transporter), member 5 
(SLC12A5) characterize tumors belonging to this group. The Gene Ontology (GO) 
categories associated with this sub-group included neuron projection and synaptic and 
axon transmission.  
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This information was then used in the study to compare against data from the brain 
transcriptosome database presented by Cahoy et al. which classifies genes into different sets 
associated with neurons, oligodendrocytes, astrocytes and cultured astroglial cells
[20]
. This 
comparison showed that genes associated with the proneural subtype were strikingly 
enriched with the oligodendrocytic signature, and not astrocytic. The classical group, on the 
other hand, is strongly related to the murine astrocytic signature. The neural sub-type was 
associated with genes involved in astrocytic and oligodendrocytic differentiation and also 
those expressed by neurons. The mesenchymal group was associated with cultured astroglial 
gene signature. Finally, it was noticed that while WHO grade III tumors and certain GBMs 
occurring in young patients mainly comprised proneural sub-type, classical and 
mesenchymal tumors were all GBMs 
[21]
 
 
Glioma Cell Invasiveness 
As mentioned above, the property of invasiveness is the first malignant characteristic that 
glioma cells acquire, and it also constitutes the chief confounding factor in therapy (see 
below). The earliest descriptions of glioma cell invasion are credited to Hans-Joachim 
Scherer, a neuropathologist who, while a political refugee in Belgium in the aftermath of 
WWII, published numerous papers that dealt extensively with the behavioral patterns of 
malignant gliomas 
[22]
. In his studies
[23]
, he designated those structures that were inherent to 
the glioma tumor and did not depend on pre-existing tissue (for example, canaliculi and 
papillary formations) as “proper structures”, whereas those that did depend on pre-existing 
tissue, were called “secondary structures” (including perivascular-, surface-, perineuronal- 
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and intrafascicular-growth). Finally, he described the formations wrought by tumor cell 
interactions with the proliferating mesenchymal tumor tissue as “tertiary structures”. 
During normal embryonic development, neural stem cells and glial progenitor cells 
extensively proliferate and travel great distances to reach their eventual destination. These 
activities are considerably diminished as the organism reaches maturity. The migratory 
pattern of glioma cells has been likened, interestingly, to that of their stem cell predecessors. 
Malignant gliomas, while similar to other malignant cells in their tendency to infiltrate, are 
nevertheless different. One reason for this difference is the limited volume of extracellular 
space available, owing to the complex mesh formed by the extensive axonal-, dendritic- and 
glial branching. However, it has been observed that in infiltrative gliomas (which includes 
Grades II, III and IV gliomas), this extracellular space increases in volume and becomes 
more irregular as extracellular matrix (ECM) components unusual for this space are seen to 
accumulate 
[23]
. Secondly, in most other malignant tumors, the cells move in and out of blood 
vessels and lymphatics, and travel via the bloodstream/lymph respectively to distant sites in 
the body. However, while glioma cells can penetrate the glial-derived portion of the blood 
vessels’ basement membrane (BM), they generally do not disrupt the endothelial portion of 
the BM, resulting in an inability of these cells to gain access to the vascular lumen 
[24]
. Thus, 
metastasis outside the brain by primary brain tumors is a relatively rare occurrence. 
Within the confines of the brain parenchyma, however, these malignant cells quite 
literally know no boundaries. In this regard, they have often been likened to “guerilla 
warriors” [23, 24] as these cells invade alone or in small groups, and abuse the “pre-existent 
supply lines”. The ECM component of the brain also includes material other than the 
vascular BM, and comprises such molecules as glycosaminoglycans (GAGs) and a few 
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structural ECM glycoproteins. The GAGs are of 4 kinds in the brain- hyaluronic acid, 
chondroitin sulfate, keratan sulfate and heparan sulfate 
[24]. Although it isn’t clear yet as to 
how glioma cells directly interact with these GAGs in their path through the ECM, it is 
presumed that specific cell-substrate interactions must be at work, to facilitate the spread of 
these cells through the corpus callosum, the anterior commissure or the optic radiation, which 
are all very frequent routes of glioma cell invasion. Besides ECM components, the neoplastic 
cells may also utilize the surfaces of neighboring neuronal and glial cells as a scaffold for 
diffusely infiltrating the parenchyma, and it has been confirmed that myelin is among the 
most permissive substrates for glioma cells for adhesion and migration. This may account for 
the common histopathological finding of glioma cells’ preferential migration in white matter 
tracts. 
It has been estimated that these tumor cells can move to a distance of 4.0±7.0 cm from 
the parent tumor 
[24]
. Using time-lapse video microscopy it was found that glioma cells when 
grown in monolayer cell cultures, migrate at different rates depending on the substrate(s) 
they are exposed to, while other experiments have shown that the brain’s ECM components- 
particularly laminin, tenascin, collagen IV and hyaluronic acid- are preferred substrates for 
tumor cell adhesion and migration 
[24]
. 
The invasion of the neoplastic cells through the surrounding normal tissue is a complex 
process. In gliomas, this process can be broken down into 3 main steps 
[24]
: A. Adherence of 
the tumor cells to the ECM via cell adhesion receptors (Integrins, CD44). B. Degradation of 
the local ECM by proteases (such as matrix metalloproteases) and C. Sending out processes 
into the newly cleared space followed shortly thereafter by migration of the cell itself 
(involving actin cytoskeleton rearrangements). 
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Angiogenesis has also been postulated to contribute significantly to the process of 
proliferation and migration of glioma cells. In fact, it has been noted that the processes of 
tumor cell invasion and neovascularization are effected by similar signaling pathways, and 
mechanisms such as adhesion, proteolysis and migration are also common to both 
[24]
. For 
example, the expression of Scatter Factor (SF)/ Hepatocyte Growth Factor (HGF) has been 
observed to strongly influence glioma cell migration as well as endothelial cell migration in 
vitro. Moreover, the endothelial cells recruited by glioma cells to vascularize the growing 
tumor are a source of proteases that assist with invasion. In turn, the invading tumor cells 
utilize the newly formed vessels as guiding structures as they invade the host. 
Clinical features of patients with gliomas and current standard of care: 
The signs and symptoms with which a patient presents can be either non-specific (such as 
due to increased intracranial pressure) or specific (secondary to the tumoral location). 
Symptoms and signs arising out of an elevation in the increased intracranial pressure 
typically include headache, vomiting, nuchal rigidity, papilledema and sixth nerve palsy. 
Headache is usually worse in the morning (presumably due to mild CO2 retention during 
sleep leading to cerebral vasodilatation) and with certain postural positions. It may be 
relieved by vomiting. It is noteworthy that the headache, while prolonged and eventually 
constant, is rarely as severe in intensity as that seen in migraine or subarachnoid hemorrhage. 
These non-specific signs and symptoms are more common in the higher-grade gliomas as 
compared to the low grade tumors.  
Clinical features owing to the location of the tumor arise due to the irritative or 
destructive nature of the tumor. The symptoms and signs produced by these masses can 
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provide valuable clues as to their location. For example, a glioma situated in the temporal 
lobe or near the motor cortex is more likely to cause seizures. Tumors situated in the fronto-
temporal cortex can cause a person to present with mental apathy or memory loss and 
personality disturbances, while those located in the fronto-parietal cortex can result in 
hemiparesis and/ or sensory loss. 
MRI imaging- including T-1 weighted images (± gadolinium contrast)  and T-2 weighted 
images-   is the investigative method of choice, as it enables localization of the tumor and 
also aids in assessing the extent of infiltration into surrounding tissue and the tumor’s 
contrast enhancing ability. GBMs usually show up as hypo-intense to intense on T-1 images 
and, if intravenous contrast has been injected, a ring-like pattern of enhancement is seen, 
suggestive of leaky vessels typical of high grade malignant gliomas 
[25]
. On T-2 weighted and 
FLAIR images, in contrast, these masses show up as hyper-intense compared to normal brain 
tissue. Some of the more advanced tools that may provide further information about the 
tumor’s biochemistry, physiology and metabolic rate include MR spectroscopy, MR 
perfusion and F-18 fluorodeoxyglucose- positron emission tomography scanning (FDG-
PET). These can also help once therapy has begun, to distinguish areas of radiation necrosis 
from tumor recurrence 
[25]
, which appear very similar on FLAIR images. 
The current standard of care of treatment for gliomas (Grade III & IV) often involves a 
combination of Surgery, Radiation therapy (RT) and Chemotherapy. Surgery enables 
debulking of the tumor which facilitates a lowering of the intracranial pressure and provides 
tissue that can be examined microscopically to form a definitive diagnosis. However, the 
median survival time with surgery alone is 3-6 months 
[26]
. While surgical resection removes 
much of the malignant tissue and provides rapid symptomatic relief, a sizeable number of 
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residual tumor cells remain that have infiltrated the brain parenchyma and cannot be 
visualized. This accounts for the frequent recurrence and dismal survival time seen in these 
patients. In order to eliminate these cells, and prevent further recurrences, the patient is 
subjected to external beam fractionated radiotherapy as well as chemotherapy. Currently, the 
most widely used drug for the latter course of therapy is temozolamide (TMZ). It has been 
demonstrated that the 2-year survival rate for patients with GBM has gone from 10% to 40% 
from 2000 to 2010, since the practice of administering TMZ concomitantly with radiation has 
been adopted 
[27]
. Despite the multimodal approach to therapy the median survival of patients 
with GBM treated with RT and TMZ is only marginally better than that in patients treated 
with RT alone (14.6 months versus 12.1 months, respectively) 
[26]
. Hence, intensive research 
is being conducted- at the bench and at the bedside- to identify new targets and better drug 
delivery techniques. These strategies are predominantly aimed at identifying proteins (growth 
factors/ growth factor receptors/cytokines/transcription factors and so on.) that are aberrantly 
expressed in tumor cells versus their normal counterparts, and restoring them to their normal 
levels. 
One such protein that has been found to be highly expressed by glioma cells is a zinc 
finger transcription factor- Wilms’ Tumor-1 (WT1) [28]. While WT1 plays a major role 
during the development of several different organ systems, its expression has been found to 
be down-regulated in most of the adult tissues- including adult human astrocytes 
[29]
. 
Previous studies in our lab have shown that although absent in normal human astrocytes, 
WT1 is expressed in a significant number of glioma cells from primary tumor specimens and 
GBM cell lines 
[28]
. The level of expression varied directly with the tumor grade, and down-
regulating the protein was found to decrease cell viability in vitro and in vivo, while 
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increasing cellular sensitivity to chemo- and radiation therapy 
[30-32]
. Given its transcription 
factor status, WT1 might mediate these effects by promoting and maintaining the malignant 
phenotype through the regulation of other genes. Little is known about the exact role of this 
protein in the pathogenesis of brain tumors: an understanding of the basic structure and 
functions of WT1 is therefore essential in order to better understand the possible 
mechanism(s) by which it can facilitate tumorigenesis. 
Wilms’ Tumor-1:  
The Wilm’s Tumor- 1 protein (WT1) is a transcription factor belonging to the zinc-finger 
family. The gene encoding this protein- wt1- was first cloned in 1990 
[33]
 and has been 
localized to the chromosome 11p13 
[34, 35]
. The mRNA transcript consists of ten exons 
[36]
, 
with the two most common splicing site variations involving the inclusion or exclusion of 
exon 5 and/or exon 9 (Fig.). Exon 5 codes for an in-frame 17-amino- acid peptide and exon 9 
codes for a tripeptide consisting of lysine, threonine, and serine (KTS). This tripeptide 
sequence is inserted in-frame between the 3
rd
 and 4
th
 zinc fingers 
[37]
. It has been 
demonstrated that presence of both splice inserts (
+
Exon 5/
+
KTS) is the most common variant 
and the absence of both (-/-) is the least 
[36]
. Further, the ratio of +KTS to –KTS isoforms, 
under normal physiological conditions, has been found to be 2:1 
[34]
. 
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Fig. 1-1: Schematic representation of the four most commonly studied isoforms of WT1. The 
inclusion or exclusion of exon 5 and KTS tripeptide give rise to these four isoforms. Numbers 1-
4 represent the zinc fingers that bind DNA. 
 
Other isoforms arise from utilizing alternate start sites that may be upstream of the 
regular start site or within the exons. Certain exons are subject to RNA editing 
[38]
 giving rise to 
additional differences in the protein product. Recently, another isoform of WT1, called 
Alternative WT1 (AWT1) was discovered, which was found to be encoded from within the first 
intron and consequently has an alternative exon 1 sequence 
[34, 38]
; this protein shows exon 
5/exon 9 splice variants similar to its regular counterpart. Another isoform has been isolated in 
different cancer cells, and its start site lies at the end of the fifth intronic sequence 
[38]
. This 
diversity in coding start sites, alternative splicing and mRNA editing contributes to the existence 
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of nearly 36 isoforms 
[38] 
known today, and does not preclude the possibility of more such 
variants being discovered in the future.  
The net result is the production of the WT1 protein, a 52-54 kDa protein 
[36]
, that serves 
as an important regulator of several growth and developmental processes. Early experiments 
using WT1 knockout mouse models showed that a congenital absence of WT1 protein led to 
death (by apoptosis) of the cells constituting the metanephric blastema, and renal agenesis by 
E12 
[39, 40]
. However, the fatality associated with WT1 gene knockout in these mouse embryos 
appears to have resulted from severe cardiovascular anomalies 
[24]
. Eliminating expression of the 
protein after E13 in these animals resulted in a disruption of differentiation of the metanephric 
mesenchyme, and not apoptotic cell death. Hence, it has been argued that the role of WT1 in 
promoting proliferation versus facilitating differentiation would depend, among other things, on 
the differentiation status of the cells involved. 
Structurally, WT1 protein consists of an amino terminal that is rich in proline and 
glutamine, and a carboxy terminal that has four adjacent Krupple-like residues, two each of 
cysteine and histidine 
[34, 35]. These residues chelate zinc, thereby forming a “zinc finger,” which 
then fits neatly into the groove of the DNA helix. The zinc fingers of the WT1 are designated I 
through IV. The N-terminal mediates interactions of the protein with RNA and other proteins. It 
is critical for the transcriptional regulatory activities of the protein as proven by deletion studies 
[34]
. The AWT1 lacks the first 147 amino acids due to an alternative start site. Consequently, it 
lacks a functional repression domain
[34]
. Madden et al. 
[41]
 showed that the transcriptional 
repression site (R) was located between amino acid residues 70 to 180, while the transcriptional 
activation domain (A) was juxtaposed, located between amino acid residues 180 to 250. Later, it 
was shown that this R domain could directly suppress the function of the A domain- by self-
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association or through interaction with a nuclear protein, and this inhibition was not cell-type 
specific 
[42]
. 
The zinc fingers have important interactions with proteins- p53, prostate apoptosis 
response factor-4 (Par-4), E1b, Ciao1 and U2AF65 
[34, 42]
, which can modify the function of the 
WT1. Zinc fingers I, II and III also contain nuclear localization signals 
[36]
. The key purpose of 
these sites though, is to serve as the DNA binding motifs of which they recognize a variety. 
These include GC- rich sites that resemble the Egr-1 consensus sequences, with which zinc 
fingers II-IV share ~61% homology (5’-GCGGGGGCG-3’) [36], a high-affinity WTE site (5’-
GCGTGGGAGT-3’) [43], or (TCC)n motif 
[44]
. 
Studies have revealed that +KTS isoforms- which account for most of the WT1 present in 
cells- could not bind the established consensus sites for WT1 with as much ease as the –KTS 
isoform 
[45-47]
. The insertion of the KTS tripeptide between the 3
rd
 and 4
th
 zinc fingers increases 
the flexibility of the linker region between them, which de-stabilizes the DNA-protein complex, 
and in turn leads to a decreased affinity of this particular isoform for DNA binding sequences 
[45, 
46]
. The alternative splicing event of WT1, to include or exclude KTS, is evolutionarily 
conserved 
[48]
, and its consequences led scientists to deliberate over its significance. Their search 
for an answer led to the discovery of an additional role for WT1- namely post-transcriptional 
regulation. 
The concept of a transcription factor that can also regulate post-transcriptional processes, 
although unusual, has been acknowledged 
[49-52]
.  The earliest findings pointing to a role for WT1 
in post-transcriptional regulation established that + and - KTS isoforms of WT1 differentially 
localized with splicing factors and transcription factors, which were RNase and DNase sensitive, 
respectively 
[53, 54]
. The RNA recognition motif was then located in the protein sequence 
[55]
, and 
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subsequent studies demonstrated that WT1 co-localized with several splicing factors- such as 
U2AF65 and WTAP among others 
[56-58]
. The presence of WT1 in nuclear poly (A)
+ 
ribonucleprotein (RNP) particles 
[54]
 and, more recently, RNP particles in acute myeloid 
leukemia cells
[59]
, its ability to shuttle between the nucleus and cytoplasm and localization of the 
protein in functional polysomes 
[60]
 all substantiated its newly proposed role. That WT1 protein 
also bound mRNA transcripts was demonstrated both in vitro and in vivo 
[48, 49, 61]
 and the zinc 
fingers were found to play a role in this RNA binding interaction 
[49, 61]
. Significantly, a protein 
that binds the poly-A tail of a mRNA transcript can increase the stability of the latter by 
protecting it from rapid destruction 
[62]
. Recent experiments have also demonstrated that 
WT1+KTS, in association with the Constitutive Transport Element (CTE), can promote the 
translation of unspliced transcripts with retained introns 
[63]
. 
 
WT1 in malignancies  
In the developing embryo, WT1 is expressed in the kidney (condensing metanephric 
blastema and podocytes), brain (area postrema), spinal cord (ventral horn motor neurons), spleen, 
the gonadal ridge mesothelium and the mesothelial lining of all organs 
[64]
. In the adult, WT1 is 
normally expressed in the glomerular epithelium of the kidney, uterine decidualcells, granulosa 
cells of the ovary and Sertoli cells of the testes 
[64]
.The importance of WT1 was first discovered 
by virtue of its absence leading to the development of Wilms’ tumor or nephroblastoma, a 
pediatric renal malignancy that was first described by Karl Max Wilms in 1899 
[34-36]
. This 
childhood tumor was thought to arise from mesenchymal blastema cells that undergo abnormal 
proliferation instead of differentiating into metanephric structures. It was, therefore, naturally 
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postulated that the WT1 functions as a tumor suppressor in this context, and most studies 
assiduously set about proving this point.  
It was subsequently discovered that most Wilms’ tumors also contained wildtype WT1 
[43]
, as opposed to earlier findings. WT1 expression is seen to be activated in a variety of other 
tissue types as the cells undergo malignant transformation. These tissues can be of epithelial 
(carcinomas of the gastrointestinal tract, lung or hepatocellular carcinoma), mesenchymal (bone- 
and soft tissue sarcomas, desmoplastic small round cell tumors or DSRCTs), ectodermal (e.g. 
gliomas, melanomas) or hematopoietic (leukemias and others) origin 
[28, 59, 65-78]
. Using 
immunohistochemical staining across a broad spectrum of tumor specimens, it was observed that 
the protein localized in different sub-cellular compartments depending on the tumor type 
[79]
. In 
tumor specimens isolated from patients with GBM, some soft tissue sarcomas, osteosarcomas, 
and malignant melanomas of the skin, WT1 was found predominantly in the cytoplasm. 
However, in certain other malignancies, such as ovarian tumors and desmoplastic small round 
cell tumors, WT1 was found in the intranuclear compartment. 
Ye at al.
 [80]
 demonstrated that in the region of its DNA-binding domain- the zinc fingers, 
WT1 could be phosphorylated in vitro by a variety of purified kinases including cAMP 
dependent kinases such as Protein Kinase A (PKA), Protein Kinase C (PKC) and Casein Kinase 
II (CKII) as well as by those obtained from nuclear extracts. Interestingly, they showed that 
phosphorylation of WT1 resulted in an impairment of its ability to bind DNA but not mRNA, 
and activating PKA significantly influenced the sub-cellular compartmental localization of WT1 
by trapping the protein in the cytoplasm. In the particular case of brain tumors, the intra-
cytoplasmic localization of the protein 
[51, 79, 81]
 might enable it to interact with the RNA, stabilize 
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it, and alter its processing and translation, leading to elevated levels or a mutant form of the 
protein. This could be one way in which WT1 can function as an oncogenic protein in gliomas. 
Moreover, the cytoplasmic localization of WT1 has been linked with its binding to actin 
filaments via the zinc finger domain 
[82]
. Interfering with actin depolymerization resulted in an 
abolition of nucleo-cytoplasmic shuttling of WT1, moved it off the cytoplasmic polysome 
fraction and impaired its ability to bind DNA and RNA. The study concluded that WT1 might 
function as an adaptor molecule, hoisting a specific subset of mRNAs on to the actin 
cytoskeleton for transporting to the target location. In a separate study using stably transduced 
TYK (ovarian carcinoma) cells, 6 other carcinomatous cell lines and one fibrosarcoma cell line 
with the different WT1 isoforms mentioned above, it was noted that in 5 out of the 8 cell lines, 
the expression of WT1(-/-) isoform induced morphological changes
[83]
. Further studies in TYK 
cells showed that these morphological changes were associated with decreased cell-substrate 
adhesion, increased cellular invasion, decreased levels of α-actinin 1 and cofilin expression, and 
an increase in gelsolin expression, i.e. an alteration in cytoskeletal dynamics. On a similar note, 
WT1 was found to be expressed in a significantly higher number of vertically growing 
melanoma cells compared to radially spreading ones, again arguing for a possible role of WT1 in 
facilitating tumor cell invasion 
[76]
. 
WT1 has also been found to be expressed in the endothelial cells of tumors, consistent 
with its role during development where it significantly contributes to the normal vascularization 
of the embryonic heart 
[84]
. 113 tumor specimens from different tissue types were analyzed and 
WT1 protein was found to be expressed in the vascular endothelial cells of 108. WT1 was also 
shown to increase the proliferation and migration of endothelial cells by regulating the levels of 
the Ets-1 transcription factor in these endothelial cells 
[85]
. 
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An important aspect of studying WT1 biology involves ascertaining its target genes. This 
list and the regulatory effect usually vary from one cell type to another. For example, while WT1 
was found to activate the transcription of E-cadherin (Cdh-1) in stably transfected mesenchymal 
fibroblasts- the NIH3T3 cells
 [102]
, in epicardial cell extracts from mouse embryos, WT1 was 
found to repress Cdh-1 expression 
[86]
. This cell-specific effect may arise from the role of WT1 
in regulating a balance between mesenchymal- epithelial transition (MET) or epithelial-
mesenchyme transition (EMT) 
[87]
. In developing kidney cells, it has been postulated that WT1 
expression facilitates cell differentiation and their exit from the cell cycle (MET). In other tissue 
types, such as the Sertoli cells and neuronal (+KTS isoforms especially) and vascular progenitor 
cells, WT1 appears to protect cells from apoptosis and facilitates cellular proliferation; in the 
developing heart, in particular, it has been found to push towards EMT- a state also seen in 
tumorigenesis. 
The transcriptional activity of WT1 has also been found to depend on its expression 
levels, the predominant isoforms (+KTS versus –KTS) and the relationship of the transcriptional 
start site to the WT1 DNA binding site (upstream, downstream or both) 
[34]
, as was noted with its 
effect on PDGF-A. The PDGF-A promoter was found to have a pair of Egr-1 consensus 
sequences upstream and a (TCC)n site downstream of the start site 
[44]
, and it was established that 
transcription of PDGF-A could be activated or repressed, depending upon whether binding of 
WT1 occurred on one or both sides of the start site, respectively 
[88-90]
.  
Thus, it is clear that there are several complex issues that need to be addressed to get a 
clearer understanding of the role that WT1 might play in tumorigenesis, and, more specifically in 
gliomagenesis. One approach would be to examine its role(s) and target genes in a very tissue- 
and cell-type specific manner, keeping in mind its ability to interact with other proteins such as 
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p53 
[91]
, which could also alter its regulatory ability. Moreover, it is rational to study the effects 
of WT1 in cell-based model systems by altering the levels of endogenously expressed WT1 
rather than inducing its expression in WT1 null cells, since the role of WT1 is very isoform- and 
concentration- sensitive as mentioned previously. 
WT1 has also been found to be a potential cancer antigen target on account of two 
features 
[92, 93]
. The first is based on its oncogenic function in promoting and maintaining the 
transformed phenotype of malignant cells which ensures its constant expression, and prohibits 
the escape of tumors from immunological surveillance by down-regulating WT1 expression. 
Moreover, WT1 is expressed by a variety of malignancies.  Hence, it could potentially be used in 
antigen-directed immunotherapy in several different malignancies. A study conducted by the 
NCI examined the potential of 75 antigenic molecules to determine which of these were 
candidate antigens for immunotherapy 
[94]
. Different criteria were utilized in this analysis in the 
following descending order of importance: (a) therapeutic function, (b) immunogenicity, (c) role 
of the antigen in oncogenicity, (d) specificity, (e) expression level and percent of antigen-
positive cells, (f) stem cell expression, (g) number of patients with antigen-positive cancers, (h) 
number of antigenic epitopes, and (i) cellular location of antigen expression. The results of the 
study showed that while there was no ideal candidate antigen, WT1 was found to be the most 
promising cancer antigen 
[94, 95]
. 
It has been pointed as a shortcoming of immunotherapy that, in comparison to 
chemotherapy, the response rate (which is given by the percentage of complete response plus 
partial response) is very low 
[95]
. However, in defense of the immune-therapeutic strategy, the 
mechanism of action is very different from that in chemotherapy in that immunotherapy utilizes 
the body’s inherent defense mechanism to kill tumor cells, which gives rise to a latent period 
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during which the tumor continues to grow. Thus, it contrasts sharply with the rapid cytolytic 
effects seen with chemotherapeutic drugs. The advantage with immunotherapy, however, is its 
low risk of toxicity, enabling repeated vaccinations. This results in disease stabilization or tumor 
shrinkage after an initial growth phase (late response) or long-term disease stabilization with 
good quality of life. Hence, it has been suggested that stable disease (SD) should be given more 
importance when evaluating response to a cancer-antigen directed vaccine, especially if the SD 
index persists long-term, as was observed to be the case with the use of WT1-specific vaccine in 
patients with GBM 
[93]
. More specifically, the disease control rate (calculated by the number of 
patients with complete response, partial response and stable disease) in the 3-month trial period 
was found to be 57.1% 
[96]
. Current studies in this context aim at determining whether combining 
WT1 peptide vaccination with the current chemotherapeutic drug of choice- TMZ- is likely to be 
more efficacious than either treatment alone. 
Conclusion 
It appears that the WT1 protein has a very complex behavioral pattern. Rather than 
classifying it as a tumor suppressor or oncogene, it should be viewed as a regulator of several 
key processes including proliferation, cell migration, angiogenesis and differentiation. Its exact 
function depends on the cell context and cell differentiation status, among other things. In glioma 
cells, it is undoubtedly a promoter of the malignant phenotype, and a thorough examination of its 
role and its target gene repertoire is, therefore, of utmost importance. This would enable the 
development of a multi-target therapeutic approach to deliver a stronger blow while 
simultaneously circumventing issues such as tumor cells resorting to alternate survival pathways. 
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Chapter 2: WT1 expression in U1242-MG and GBM-6 cell lines promotes cellular 
invasiveness. 
 
Abstract 
 
WT1 expression was previously found in our laboratory to be up-regulated in a 
significant number of glioma cell lines and primary tumor specimens, and this transcription 
factor was noted to significantly impact cellular invasiveness and cellular proliferation (in vitro 
and in vivo) in U251-MG cells. This study aimed to analyze its expression in two hitherto 
unexamined cell lines- U1242-MG and GBM-6- both of which are noted for their invasive 
potential 
[99,100]
. Using Real Time RT-PCR and Western blotting, we found that WT1 was 
expressed in both cell lines. Moreover, silencing WT1 expression in these cell lines was 
associated with a remarkable decrease in their invasiveness in vitro but the proliferative rates of 
the siRNA-treated cells were similar to their control counterparts. We also sought to examine the 
effects of WT1 silencing on the expression of some of the previously established target genes- 
PDGF-A, Snai1, E-cadherin and IGF-1R, to account for the functional effects of WT1. While no 
consistent effect was noted upon manipulating WT1 levels on the expression of PDGF-A, Snai1 
and E-cadherin, the amount of WT1 inversely correlated with IGF-1R expression in U251-MG 
cells at the RNA and protein levels. To ascertain whether the increased IGF-1R expression could 
account for increased cell death seen with WT1 silencing, we performed cell viability assays on 
cells treated with IGF-1R siRNA. Our results show a trend towards a decrease in cell viability 
upon IGF-1R silencing, suggesting that the decreased cell proliferation caused by WT1 down-
regulation in U251-MG cells does not involve IGF-1R mediated paraptosis. We conclude that the 
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target genes previously established for WT1 are not upheld in the glioma cell lines studied, and 
further studies are necessary to elucidate its downstream targets in the specific context of glioma 
cells. 
Introduction 
Malignant gliomas include Grade III and Grade IV glial tumors and constitute an 
extremely formidable group of malignant neoplasms that are highly aggressive and resistant to 
most conventional modes of therapy. Studies are in progress to identify molecules that can be 
targeted to achieve a better therapeutic outcome. One such intracellular protein that has been 
implicated for its potential role in the neoplastic progress is the zinc finger transcription factor- 
Wilms’ Tumor-1 (WT1).  
WT1 was thought to function as a tumor-suppressor for several years following its initial 
discovery, and it has been well established as a co-ordinator of several key processes during 
embryonic development 
[36, 64]
. Most of its functional studies were conducted in NIH3T3 and 
HEK293 cells 
[41, 89, 95]
, wherein reporter assays mostly showed a repressive effect on the 
transcriptional regulation of most oncogenic proteins. This was followed by a diametrically 
opposing change towards ascribing an oncogenic role to WT1, as its unusual expression in 
malignant cells of different tissue types became increasingly evident 
[59, 65-78]
. In most of these 
tumors, it was noted that down-regulating the endogenous expression of WT1 led to a reversal of 
the malignant phenotype of the tumor cells 
[97, 98]
. Moreover, it was also demonstrated that not 
only did WT1 regulate the expression of its targets at the transcriptional level, but it could also 
exert its influence beyond transcription 
[53, 54]
. At present, researchers studying the intriguing 
facets of this very complex protein have arrived at the conclusion that interpretation of the roles 
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and functions of WT1 should be viewed strictly in the context of the the specific features of the 
cells under investigation, including cell type, cell differentiation status, DNA binding sites 
available and the isoforms of WT1. 
We have previously demonstrated that the aberrant expression of WT1 in glioma cells 
contributes to enhanced cell proliferation in vitro and in vivo and resistance to radiation- and 
chemotherapy 
[28, 30-32]
. Our findings on the effect of WT1 on cell proliferation are in agreement 
with other studies involving glioma cells as well as other tumors. While it has been shown that 
immunologically targeting WT1 in patients with gliomas has had promising results 
[96]
, aspects 
of its functional biology in these tumors remains largely unknown.  Here, we show for the first 
time that WT1 is expressed in two highly invasive glioma cell lines- U1242-MG and GBM-6. In 
these cells, WT1 was found to dramatically enhance cell invasion but not proliferation. Our 
rationale for selecting these two cell lines was based on previous studies by other groups that 
have established these cells as closely mimicking the pathology of GBM when implanted 
orthotopically in athymic mice 
[99, 100]
. 
In this study, we also sought to identify potential molecular targets for WT1 in 
facilitating these malignant phenotypic features of glial neoplasms. To do this, we examined the 
effect of manipulating WT1 on four of its previously established target genes- IGF-1R 
[101]
, 
PDGF-A 
[88-90]
, Snai1 and E-cadherin 
[86, 102]
. The latter three candidate proteins were chosen 
mainly for their facilitation of the invasive process (PDGF-A and Snai1 
[14, 103, 104]
) or for 
inhibiting it (E-cadherin 
[104, 105]
). The up-regulation of IGF-1R following WT1 silencing in 
T98G 
[30]
 cells was previously postulated to contribute to a non-apoptotic form of cell death 
called paraptosis 
[30, 106]
. We set out to ascertain the validity of this hypothesis by first confirming 
the inverse correlation between these two proteins in U251-MG cells, followed by siRNA 
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mediated IGF-1R silencing to determine whether it led to enhanced cell proliferation. Our 
findings show that WT1 is consistently and inversely correlated with IGF-1R expression in 
U251-MG cells. This inverse correlation, however, was not found to explain the effect of WT1 
on promoting cellular proliferation. We also noted a lack of consistent correlation between the 
expression levels of WT1 and the pro-invasive proteins that we examined- PDGF-A, Snai1 and 
E-cadherin in the three cell lines tested. 
Materials & Methods 
Cell culture: Human glioma cell line, U251-MG, was obtained from the ATCC, U1242-MG and 
GBM-6 cells were kindly gifted by Dr. James Van Brocklyn and Dr. C. David James/Dr. Paul 
Dent respectively. All cells were cultured in Dulbecco's modified Eagle's medium containing 
10% fetal bovine serum, glutamine, nonessential amino acids, and 1% penicillin-streptomycin in 
a humidified atmosphere of 5% CO2. 
siRNA transfections: Cells were plated in 6-well plates at a density of 1.5-2 x 10
5
 cells per well. 
24 hours after plating, the cells were transfected as described previously 
[32]
. Briefly, 
transfections were carried out using the pre-designed siGENOME SMARTpool (Dharmacon) 
containing 4 siRNA sequences directed against WT1 and/ or IGF-1R. A pool of 4 non-targeting 
siRNA sequences (siCONTROL Non-Targeting Pool, Dharmacon) was used as a control and 
will be referred to as siScramble (Scr). The final concentrations of Scr control and anti-WT1 
siRNA were 100nM, and for siRNA directed against IGF-1R, the final concentration was 50nM. 
These siRNA concentrations were determined by a series of optimization experiments. 24 hours 
after transfection, 10% DMEM supplemented with 1% penicillin/streptomycin was added. 48 
hours after transfection, the cells were harvested with trypsin, and following re-suspension of the 
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cell pellet in 10% DMEM, the cells were re-plated for RNA extraction for qRT-PCR, protein 
extraction for Western Blotting and for cell proliferation assays and/ or invasion assays. 
Plasmid construction and transient transfection: WT1 expression plasmids (in pcDNA3, 
Invitrogen) containing either WT1 (+/+) or WT1 (-/+) isoforms were kindly provided by Dr. 
Charles T. Roberts, Jr. and have been described previously 
[32]
. Cells were plated in triplicate at a 
density of 2 x l0
5
 in six well plates and allowed to attach overnight in DMEM without 
penicillin/streptomycin. Cells were transfected with a mixture of 3µl Lipofectamine 2000 
(Invitrogen) and 1.0µg plasmid diluted in 500µ1 DMEM without fetal bovine serum or 
penicillin-streptomycin and incubated for 4 hours at 37
0
 C. After 4 hours, cells were 
supplemented with 1.5 ml DMEM with 10% fetal bovine serum without penicillin-streptomycin. 
Twenty four hours after transfection, the conditioned media was removed and replaced with 2.0 
ml fresh DMEM with 10% fetal bovine serum without penicillin/streptomycin. Forty eight hours 
after transfection, cells were selected in DMEM containing 600µg/ml Geneticin (Invitrogen). 
Selection media was changed every 4 days. 
RNA Extraction: Total RNA was extracted using Trizol (Invitrogen) as per the manufacturer’s 
protocol. Following RNA extraction, the RNA content was quantified using the 
spectrophotometer, and roughly 12µg of RNA per sample were subjected to DNase treatment 
using RQ1 DNase (Promega). Samples were then analyzed using Real Time RT-PCR. Synthesis 
of probes and primers for WT1 was carried out at the VCU Nucleic Acid Research Facilities. 
The Taqman primer mixes for the target genes were purchased from Applied Biosystems. All 
Real Time PCR reactions were performed at the VCU Nucleic Acid Research Facilities. 
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Western Blotting: Protein was extracted from cell lines using SDS buffer (50 mM Tris-C1, 1% 
SDS, 10% glycerol) supplemented with protease inhibitors. The concentration of protein was 
determined by DC protein assay (Bio Rad). For protein analysis of cells transfected with WTl, 
10µg of total protein lysate were separated by SDS-PAGE and transferred to nitrocellulose 
membrane as per manufacturers' protocol (Invitrogen). The membrane was then blocked with 5% 
nonfat milk solution for 1 hour at room temperature. Mouse anti-WT1 monoclonal antibody 
(1:200, Clone: 6F-H2, Dako), rabbit anti-IGF-1R polyclonal antibody (1:1000, Cell Signaling) 
were diluted in blocking buffer and the blots were incubated with the respective primary 
antibodies overnight at 4
0
 C. The membranes were then washed six times in tris buffered saline 
containing 0.05% Tween-20 before and after a 1-hour incubation at room temperature with 
horseradish peroxidase-conjugated anti-mouse (1:2000) and anti-rabbit (1: 3000) secondary 
antibodies directed against anti-WT1 and anti-IGF-1R, respectively. Anti-Cyclophilin A 
monoclonal antibody (1: 30000, Upstate Biotechnology) or Anti-beta actin monoclonal antibody 
(1:5000, Sigma) was used as a control for protein loading. Blots immunostained for WT1 were 
developed using Pierce Supersignal West Dura Substrate and those for IGF-1R were developed 
using the ECL™ Western Blotting Detection Reagents (Amersham Biosciences). 
Cell proliferation Assay: Cellular proliferation was measured at specified time-points after 
transfection using the CellTiter-Glo® Luminescent Cell Viability assay (Promega). Cells were 
plated in 3-5 replicates per treatment group in opaque 96-well plates 48 hours after transfection. 
These cells were lysed for 15 minutes in Cell-titer Glo ATP viability assay reagents as per the 
protocol at specified time points following transfection. Relative luminescence was then detected 
on a Lumistar luminescence plate reader (BMG Technologies). Each experiment was performed 
in triplicate. Validation studies in our laboratory demonstrate that this assay provides highly 
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reproducible results with strong linear correlation (R
2
 > 0.98) to cell counting with the Trypan 
exclusion technique, and with high throughput capacity (data not shown). 
Invasion assay: Matrigel (BD Biosciences), previously aliquoted was thawed at 4
0
 C on ice 
overnight before use. 48 hours post-transfection, cells were plated in triplicate on Matrigel-
coated 8.0µm Pore Polycarbonate Membrane Inserts of 6.5mm Transwell® plates (Corning- 
3422) at a density of 5000 cells/500µL.  96 hours following transfection, media was removed 
from the filters and the lower chambers, the upper part of each filter was scraped with cotton-
tipped applicators to remove the cells that had not invaded, and each lower chamber was rinsed 
with PBS. 200µL of trypsin-EDTA (Invitrogen) was added to each chamber to harvest the cells, 
and 800µL of 10% DMEM was used to neutralize the enzyme. The lower part of each filter was 
rinsed with media, in order to collect cells that had invaded through the Matrigel-coated insert, 
but not adhered to the base of the lower chamber. After centrifugation at 1000 rpm for 5 minutes 
to collect the cells, the supernatant was removed from each tube, and fresh media was added to a 
volume of 500µl. The entire volume was then plated (100µl/well) into an opaque 96-well plate 
for assaying the ATP content as described above. Each experiment was conducted in triplicate. 
Statistical Analysis: All comparisons were made between two groups- cells treated with non-
targeting siRNA (scr) and those treated with siRNA directed against WT1 or IGF-1R. Each 
experiment was performed at least three times. Results were analyzed using Student’s T-test 
(two-tailed, paired). Significance level was set at p value <0.05. Error bars were calculated using 
standard deviation measurements. 
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Results 
WT1 is expressed in GBM-6 and U1242-MG cell lines. Using western blotting, we detected 
WT1 expression in these cell lines (Fig.2-1). Cell extracts from the prostatic carcinoma cell line 
(PC3) was used as a positive control for WT1. Both GBM6 and U1242-MG show the 
characteristic WT1 double band, suggesting the possibility of the + and – exon 5 variants that 
differ by 17 amino acids, at the predicted molecular weight level (52-54 kDa). 
 
Figure 2-1: WT1 expression in GBM-6 and U1242-MG cells. Using western blotting technique, 
WT1 protein was detected in these highly invasive cell lines. 20 µg of protein was loaded in each 
lane. Cell lysates in Lane A: PC3 (control), lane B: GBM-6, lane C: U1242-MG. 
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Silencing WT1 inhibits cellular invasiveness in GBM-6 and U1242-MG cells in vitro. Using 
siRNA directed against WT1, we confirmed efficient silencing of this transcription factor by 
Real Time RT-PCR (Fig.2-2A). On the third day after transfection, we found that WT1 level in 
GBM-6 cells that had been treated with si- WT1 was 14.44% (S.D.: ± 2.89) of that seen in its 
control counterpart that had been treated with non-targeting siRNA (n=3, **p≤0.001). In U1242-
MG cells, there was less knockdown (50.47% [S.D.: ± 3.49] of control, which was nevertheless 
highly significant (n=3, **p≤0.001).  
We observed that these decreases in cellular content of WT1 remarkably depressed the 
invasive capacity of these cells (Fig.2-2B). In GBM-6 cells, there was nearly a 95% decrease 
(S.D.: ± 22.65) in the ability of the siWT1-treated cells to invade through the Matrigel-coated 
filter (n=3, *p≤0.05) compared to the control cells, while in U1242-MG cells, silencing WT1 
caused a decrease in cellular invasiveness to 20.62% (S.D.: ± 1.12) of the control cells (n=3 
**p≤0.001). These differences in the ability to invade could potentially be accounted for by 
decreased proliferative rates in the siRNA transfected cells versus control cells. Hence, we 
performed cell viability assays on these same groups of cells. Our results showed that the growth 
rates of control and treated cells were not significantly different across three independent 
experiments (Fig.2-2C). Also, based on our previous experiments we found no statistically 
significant differences between untreated and non-targeting siRNA (scr) treated cell groups. 
Hence, we show only comparisons between the scr and targeting siRNA treated groups. 
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Figure 2-2: WT1 silencing in GBM-6 and U1242-MG cells causes decrease in cellular 
invasiveness. A. RNA was extracted at day 3 post-transfection. WT1 silencing was confirmed 
using Real Time RT-PCR (n=3, p ≤ 0.001). WT1 expression in siWT1 treated cells is first 
normalized to the loading control and expressed as a percentage of their control counterparts. 
B.WT1 down-regulation was associated with a decrease in GBM-6 and U1242-MG cellular 
invasiveness at day 4 post-transfection (n=3, *p < 0.05, **p< 0.001; RLU= relative 
luminescence units). Cell invasiveness in WT1 silenced cells is expressed by calculating the ATP 
content in the si groups versus scr groups and then expressed as a percentage of that seen in 
control cells. C. GBM-6 and U1242-MG cells that were treated with siRNA directed against 
WT1 exhibited proliferative rates similar to the cells that were treated with non-targeting siRNA 
(n=3; RLU= relative luminescence units). 
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WT1 expression in U251MG cells correlates inversely with IGF-1R levels, but not with 
PDGF-A. We have previously shown a significant decrease in cellular proliferation in vitro and 
in vivo with WT1 silencing 
[31]
. Our current results in U1242-MG and GBM-6 cells also confirm 
our previous findings in U251-MG cells that WT1 plays a major role in regulating cellular 
invasiveness. Based on these findings, we chose PDGF-A, Snai1, E-cadherin and IGF-1R to 
determine if WT1 might mediate these effects on invasiveness and proliferation by regulating the 
expression(s) of any of these genes. We could find no consistent effect upon manipulating WT1 
expression on the level of PDGF-A, Snai1 or E-cadherin (data not shown).  
However, in U251-MG cells, silencing WT1 was associated with an increase in IGF-1R 
protein expression (Fig. 2-3A). We transduced U251-MG cells with plasmids containing WT1 
(+/+) and (-/+) isoforms as these are the most predominant isoforms seen in glioma cells. The 
increase in WT1 expression as a result of this manipulation was associated with a decrease in 
IGF-1R expression at the RNA level as shown in Fig. 2-3B (n=3). Over-expressing WT1 (+/+) 
resulted in a marked increase in WT1 protein expression and was accompanied by a reduction of 
approximately 50% (S.D.: ± 13.35) in IGF-1R protein expression while only a small increase in 
WT1 protein expression with WT1 (-/+) transfection paradoxically increased IGF-1R protein 
levels (Fig.2-3C). Notably, silencing WT1 expression in U1242-MG and GBM-6 cells had no 
effect on IGF-1R expression levels (data not shown). Thus, it appears that in U251-MG cells, 
and as per previous studies in T98G cells 
[30]
, WT1 expression correlates inversely with IGF-1R.
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Figure 2-3: WT1 levels vary inversely with expression of IGF-1R in U251MG cells. A. WT1 
silencing was associated with increased IGF1R expression at the protein level (representative 
blot). 20 µg protein was loaded in each lane. Cyclophilin was used as a control to ensure equal 
protein loading. B. WT1 over-expression was carried out using WT1 (+/+) and WT1 (-/+) 
isoform containing plasmids. Cells transduced with an empty plasmid served as Vector Control 
(VC). IGF-1R expression was specifically and consistently low in cells that had been transfected 
with WT1 (+/+) plasmid at the RNA (n=3, p=0.05) and (Fig.2-3C) protein levels. U251-MG 
cells transfected with WT1 (-/+) did not exhibit a decrease in IGF-1R protein level, despite a 
decrease in IGF-1R mRNA levels. Representative blot is shown. All experiments were replicated 
≥ 3 times with similar results. 
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IGF1R silencing decreases cellular proliferation in U251-MG cells. The increase in IGF1R 
expression seen as a result of WT1 silencing could potentially decrease the ability of these cells 
to proliferate by means of a non-apoptotic cell death called paraptosis 
[106]
. Conversely, it could 
be a compensatory response by the cells to escape death due to eliminating the effects of WT1. 
In order to ascertain which of these two scenarios was more likely, U251-MG cells were 
transfected with siRNA against IGF-1R. Initial optimization experiments revealed that using a 
concentration of siRNA of 50nM delivered a 69% decrease in IGF-1R protein even at day 5 
following transfection (Fig.2-4A). This dose was then used to determine the optimum time 
period of IGF-1R knockdown, and we found that this was at day 2 and day 3 following 
transfection (Fig. 2-4B). On the 2
nd
 post-transfection day, the IGF-1R mRNA level in si cells was 
about 42.7% the level in scr controls (n=3, p< 0.01) and 51.42% of the level in untreated control 
cells (n=3, p< 0.5). Cell proliferation assays were carried out until day 5 post-transfection. At 
this time point, we observed that the IGF-1R mRNA level in siRNA treated cells was still 
decreased to 58.93% and 71.79% of the levels in the scr and control cells respectively (n=3, p > 
0.05). While there was no difference in proliferative abilities between the three experimental 
groups up to day 4 despite maximal RNA knockdown at days 2 and 3 post-transfection, silencing 
IGF-1R expression was generally found to lead to a decrease in proliferative rates (Fig.2-4C). 
However, this was not observed to be statistically significant between the non-targeting siRNA 
and IGF-1R siRNA treated groups, but only between the untreated and IGF-1R siRNA treated 
groups (n=3, *p<0.05).
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Fig.2-4:  IGF-1R silencing in U251-MG cells decreases cellular proliferation. A. Western Blot 
densitometry results showing the effect of IGF-1R knockdown at day 5 post-transfection. 
Optimization experiments were conducted with different concentrations of siIGF-1R: 5-, 10-, 50- 
and 100 nM (n=1). Maximal knockdown efficacy at this time-point was seen with [siIGF-1R] = 
50nM. B. Real Time RT-PCR data showing maximal IGF-1R levels suppression between scr and 
si groups on Days 2 and 3 post-transfection, and between untreated (ctrl), non-targeting siRNA 
treated (scr) and siWT1 treated (si) groups on Day 3 post-transfection (n=3, * p < 0.05, ** p< 
0.01). C. Cell proliferation assay demonstrating a significant but small decrease in cell viability 
in siIGF-1R treated cells as compared to the untreated cells at day 5 post-transfection (n=3, *p< 
0.04; RLU= relative luminescence units). No statistical significance was observed between 
scrambled RNA and siRNA treatment groups. 
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Discussion 
We have previously shown that WT1, a zinc finger transcription factor, is expressed in a 
significant number of glioma cells, and impacted tumor cell proliferation in U251-MG and T-
98G, invasiveness, and resistance to radiation- and chemotherapy 
[28, 30-32]
. In this study, we have 
shown that WT1 is expressed in two additional glioma cell lines- U1242-MG and GBM-6 and in 
these cells it is seen powerfully affect their invasive abilities. A decrease in the endogenous 
expression of WT1 decreases the invasive capacity of glioma cells, despite equivalent 
proliferative rates. These differences in invasiveness appear not to involve the PDGF-A or Snai1 
signaling pathways or down-regulation of E-cadherin. We also demonstrate here that in U251-
MG cells, WT1 level is inversely correlated with that of IGF-1R, similar to our previous findings 
in T98-G cells 
[30]
. IGF-1R silencing, however, resulted in a trend towards decreased cell 
viability, suggesting that its up-regulation with WT1 silencing might represent activation of an 
alternate survival pathway. 
In malignant cells, contrary to what was believed earlier, recent evidence has leaned more 
in favor of a putative oncogenic role(s) ascribable to WT1 
[30, 31, 65-79, 85]
. It is worth reiterating 
that the functions of this highly complex protein are variable and should therefore be interpreted 
strictly based on the cell context in which they are studied. It has been established that the ability 
of WT1 to promote proliferation versus differentiation also depends upon the differentiation 
status of the cells involved. For example, its ability to induce mesenchymal-to-epithelial 
transformation (MET) leads to an exit from the cell cycle of developing cells in the kidney and 
their consequent differentiation to generate nephrons 
[38]
. However, in other tissue types- such as 
neuronal and vascular progenitor cells- WT1 protects cells from apoptosis, and maintains cells in 
the proliferative, undifferentiated state 
[38]
. Further, we postulate that the ability of WT1 to 
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influence proliferation in glioma cells might also depend upon other factors, such as the PTEN 
status and/ or its interactions with other proteins. It was interesting to note that in U251-MG and 
T98G cells, where WT1 significantly impacted cellular proliferation, the PTEN status was either 
null or mutated 
[107, 108]
. In U1242-MG and GBM-6 cells, on the other hand, WT1 was found to 
influence migratory properties and not proliferation. Both these cell lines have wildtype PTEN 
[109, 110]
. There is no documentation at present regarding the influence of PTEN status on the 
ability of WT1 to regulate cell proliferation. Interestingly, there is evidence that the presence of 
wildtype PTEN acts as a deterrent in the cellular invasiveness process by mechanisms that are 
independent of its effect on cellular proliferation 
[3]
. Yet, despite the presence of wildtype PTEN 
in U1242-MG and GBM-6 cells, there appears to be no inhibition of invasion, in the presence of 
WT1. Thus, a complex interplay exists between proteins belonging to different intracellular 
signaling pathways in a malignant cell, and it would be interesting to determine if an interaction 
between WT1 and PTEN contribute towards the functional effects of each in glioma cells. 
There have been several reports implicating WT1 in fostering invasiveness of different 
types of tumor cells 
[76, 82, 83, 111, 112]
. More recently, a new binding partner for WT1 has been 
revealed in actin- a key component of the cytoskeleton that dictates such important processes as 
changes in cell shape, movement and cell division 
[82]
. It is clear from our results that in glioma 
cells, WT1 co-ordinates cellular motility. The earliest studies that sought to determine WT1’s 
target genes highlighted PDGF-A as being both- transcriptionally activated as well as repressed 
by WT1, depending upon the cell context and the locations of the binding sites for WT1 on its 
promoter 
[88-90]
. Considerable data exists demonstrating the importance of the PDGF-signaling 
pathway in glial neoplasms (reviewed in 15). However, in our experimental models, we failed to 
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find a consistent correlation between WT1 and PDGF-A expression levels, and therefore rule out 
this interaction as an explanation to the former’s impact on cell migration. 
Snai1 and E-cadherin are both well established regulators of the crucial process of 
epithelial-mesenchymal transition (EMT) (reviewed in 113). Snai1 down-regulates the 
expression of E-cadherin and pushes the cell towards a more undifferentiated phenotype, with a 
consequent decrease in inter-cellular adhesive forces (also a consequence of decreased E-
cadherin levels) and increase in cellular motility 
[33, 103-105, 114]
. In vascular progenitor cells, Snai1 
was shown to be transcriptionally activated by WT1, while E-cadherin was shown to be 
repressed 
[86]
. However, altered expression of these genes could not be shown to explain the 
enhanced cell motility conferred upon glioma cells by WT1. 
IGF-1R is known to be a key factor in promoting cellular transformation. However, there 
have been reports ascribing a unique role to this growth factor receptor, in promoting a non-
apoptotic form of programmed cell death called paraptosis 
[106]
. Similar to the findings described 
in that study, we have previously shown that in T98G cells treated with WT1 siRNA, there were 
no discernible differences in markers for apoptosis or autophagy, but the cell viability was, 
nevertheless, markedly decreased, along with inverted light microscopy features of prominent 
cytoplasmic pleomorphism and vacuolization 
[30]
. These changes were associated with an up-
regulation in IGF-1R expression in this cell line, as was seen with the U251-MG cells. 
Surprisingly however, when we silenced IGF-1R expression using siRNA in U251-MG cells, the 
cells displayed a decrease in their proliferative capacity. This suggested that the up-regulation of 
IGF-1R with WT1 silencing was not a satisfactory mechanism to explain the decrease in cell 
viability, but, in fact, might point to activation of an alternate survival pathway that these 
malignant cells are notorious for. Interestingly, the maximal knockdown of IGF-1R mRNA was 
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observed at days 2- and 3 post- transfection, but cell proliferation rates were noticeably low only 
at day 5 post-transfection at which time point the protein levels of IGF-1R were also low. This 
observed delay in the effect on cell proliferation might be accounted for by pre-existing 
functional IGF-1R protein that continues to promote the proliferative potential of tumor cells in 
the immediate post-transfection period. This can be roughly evaluated by assessing the levels of 
phosphor-IGF1R- the activated form of the receptor protein. 
To summarize, we have demonstrated a novel role for WT1 in enabling glioma cells to 
invade, in vitro. The target gene/s that help(s) it achieve this process, as well as those that enable 
it to promote cellular proliferation, remain(s) to be discovered and form the focus of our current 
and future studies. Considering that it is the property of cellular invasiveness that makes these 
tumors difficult to treat, the need to identify the molecules mediating this process can easily be 
recognized as imperative. A more in-depth examination of its target gene(s) and their 
contributions will undoubtedly facilitate the development of a multi-targeted therapeutic 
strategy, which might be our only hope in effecting a cure for this deadly disease. 
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Chapter 3: Candidate target genes for WT1 in glioma cells- Possible involvement of CD97 
in mediating its effects on glioma cell invasiveness. 
 
Abstract 
 
WT1 is a zinc finger transcription factor with well-established roles in the development 
of different organ systems during embryonic development. Its expression is absent in normal 
adult astrocytes, but is switched back on in astrocytomas, and the more aggressive tumors exhibit 
increasing levels of expression. While in U251-MG and T-98G glioma cell lines, this protein has 
been demonstrated to influence tumor cell proliferation, it has also been found to play a very 
prominent role in mediating cell invasiveness as we have shown previously. Although its 
functional effects have been studied to some extent and this knowledge has been employed in 
devising therapeutic strategies to immunologically target WT1, little is known yet about the 
molecular allies that help it mediate these oncogenic functions in the specific context of glioma 
cells. Here, we present for the first time in glioma cells, the identities of some of these proteins. 
Using gene expression analysis, we found that silencing the endogenous expression of WT1 in 
U251-MG cells was associated with the down-regulation of several genes that have putative 
oncogenic functions, and the up-regulation of some proteins considered to have tumor-
suppressor effects. When compared to normal human astrocytes, the expression levels of most of 
the candidate target genes that directly correlated with WT1 were higher in glioma cells. We 
validated the microarray findings at the RNA level using Real Time RT-PCR, and also 
confirmed these correlations in two other glioma cell lines- U1242-MG and GBM-6- which are 
well known for their high invasive capacities
 [99,100]
. One of the genes that was found to be 
consistently and significantly decreased upon WT1 silencing in all three cell lines studied was 
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CD97. We sought to ascertain whether this protein, which has been implicated in facilitating cell 
invasiveness and even angiogenesis in gastrointestinal carcinomas and other tumors, has any 
effect in mediating the pro-invasive effects of WT1. Our invasion assay results in vitro showed 
that cells that had been treated with siRNA directed against CD97 displayed a markedly lower 
propensity to invade as compared to their control counterparts. We conclude that CD97 has a 
very important role to play in dictating one of the most characteristic features of glial tumor 
cells, and further studies are imperative to clarify the extent of its impact. 
Introduction 
The Wilms’ Tumor-1 (WT1) protein was originally believed to function as a tumor-
suppressor. Early studies showed that the protein repressed the transcription of several 
oncogenes such as PDGF-A, TGF-beta, EGFR, IGF-1R and so on, and increased the expression 
of genes that prevented malignant transformation such as E-cadherin, and pro-apoptotic 
molecules (reviewed in 34). This impression, however, began to undergo a remarkable 
transformation, as it was increasingly noticed that the ability of WT1 to transcriptionally activate 
or repress a putative target depended largely on the cell type, the isoforms studied, the number of 
WT1 binding sites present on the target promoter and other factors. The factor that most put into 
serious doubt WT1’s tumor-suppressor status, however, was the escalating incidence of its 
discovery in malignant cells from several different tissue types (reviewed in 115). A key 
regulator of various developmental processes, WT1 expression was known to be switched off as 
tissues developed into the normal adult stage 
[36, 38-40]
. However, wildtype WT1 was found to be 
expressed in leukemias and other hematopoietic malignancies, lung and breast cancers, 
gastrointestinal cancers, sarcomas, tumors in the head and neck, reproductive organ neoplasms, 
and gliomas (reviewed in 115). In most or all of these tumors, WT1 was not merely expressed, 
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but appeared to play a decisive role in promoting proliferation, invasion and/ or angiogenesis 
[30, 
31, 65-80, 82-85]
. 
We have previously demonstrated aberrant WT1 expression in a significant number of 
glioma cell lines and tumor specimens 
[28]
. The predominant WT1 isoforms expressed in these 
cells was discovered to be the one containing exon 5 and the tripeptide KTS between zinc fingers 
3 & 4 (WT1 +/+). Our studies showed that glioma cells that had endogenous WT1 expression 
relied heavily on the protein for their growth and motility. WT1 also conferred upon these cells 
resistance to radiation therapy and some chemotherapeutic agents 
[30, 32]
. The question then arose 
from these observations: How does WT1 mediate these effects in glial neoplasms?  
Given its structural identity- a zinc finger transcription factor- and its functional history, 
it seemed logical to hypothesize that WT1 might regulate the transcription (or post-
transcriptional expression) of other genes, which might then directly cause the above-mentioned 
effects. However, when we looked for possible correlations between WT1 and its previously 
established targets- PDGF-A and IGF-1R, we found that in glioma cells WT1 had no consistent 
effect on PDGF-A, while its inverse correlation with IGF-1R levels appeared not to be related to 
a regulatory mechanism. Therefore, in order to identify which genes  might vary in glioma cells 
in their expression patterns as a result of WT1-mediated regulation, we utilized the gene 
expression profiling technique to characterize differential gene expression. This method enables 
rapid screening of the entire genome to find all the possible candidate genes that are 
differentially expressed as a result of any manipulations. Our analyses revealed the identity of 
some such presumed or established oncogenes whose levels paralleled that of WT1 in glioma 
cells- PDGF-D, TYMS, INPP5A, CD97 and FAM57A. Genes that were increased as a result of 
WT1 suppression, on the other hand, included putative tumor suppressors- such as LZTS1, 
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TIMP3, MAFF, WIPI-1 and so on. We selected CD97 for further investigations, based on its 
consistent and direct correlation with WT1 across the GBM cell lines examined and because of 
its putative roles in facilitating cell invasiveness and neo-angiogenesis in gastrointestinal and 
thyroid tumors. This is the first time that expression of this protein has been reported in glial 
neoplastic cells. 
CD97 is a cell surface receptor that belongs to the Adhesion-G-Protein Coupled Receptor 
(GPCR) family and is therefore characterized by heptahelical hydrophobic segments that form 
the seven-transmembrane spanning domain (TM7), an extracellular N-terminus containing 
epidermal growth factor (EGF)- like structural domains (comprising the α-subunit) and an 
intracellular C-terminus 
[116]
. Through alternative splicing of the mRNA transcript, three 
isoforms of the α-subunit of CD97 can be generated, that differ in the number of EGF repeats 
they contain- these isoforms are hCD97 (EGF 1,2,5), hCD97 (EGF 1,2,3,5) and hCD97 (EGF 
1,2,3,4,5) 
[117]
. Also present on the nucleotide sequence of the extracellular segment, after the 
EGF-like repeats and before the first membrane-spanning sequence at position 318 is an RGD 
motif. This motif has been established to act as a binding site for several classes of integrins, 
which are well known for their role in mediating attachment to the extracellular matrix and to 
other cells 
[117]
. The ligands that have been found to bind CD97 include CD55/ Decay 
Accelerating Factor (DAF) (involved in protection from complement mediated attack and lysis), 
Chondroitin Sulfate (a glycosaminoglycan that affects cell attachment), and α5β1 integrin 
[118]
. 
Interestingly, the intracellular signaling mechanism(s) by which CD97 and other EGF-TM7 
family members might act is/are yet unclear 
[119]
. 
CD97 expression has been reported mainly in leukocytes and in this group, it has been 
found predominantly in myeloid cells. Besides these, its expression has also been reported in 
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smooth muscle cells and in epithelial tumors 
[118]
. Its expression in thyroid carcinoma cells has 
been linked with promoting de-differentiation 
[120]
, while in colorectal and gastric carcinomas 
and fibrosarcomas, its expression has been alleged to promote cellular invasiveness 
[119]
. Our 
results corroborated the findings from these earlier studies and we confirm that in glioma cells, 
too, CD97 appears to influence cellular invasiveness. Future studies will be directed at 
confirming whether WT1 regulates expression of this protein at the transcriptional and/or at the 
post-transcriptional level(s). 
Materials & Methods 
Cell culture and reagents: Normal human astrocyte RNA (Cat.No.: 1805) was procured from 
ScienCell Research Laboratories. Cell lines used are described on page 31. 
siRNA transfections: The procedure for siRNA transfection has also been described on page 31. 
The final concentration of non-targeting siRNA control, anti-WT1 and anti-CD97 siRNA was 
100nM and determined by performing optimization experiments. 48 hours after transfection, the 
cells were harvested with trypsin, and following re-suspension of the cell pellet in 10% DMEM, 
the cells were re-plated for RNA extraction for qRT-PCR and microarray analyses, protein 
extraction for western blotting and for cell proliferation assays and/ or invasion assays. 
RNA extraction: The technique for RNA extraction and processing was similar to that described 
on page 32. 
Western blotting: Western blotting using cell lysates was performed exactly as described on page 
33. Rabbit anti-CD97 polyclonal antibody (Abcam, 1:200) were diluted in blocking buffer and 
the blots were incubated with the respective primary antibodies overnight at 4
0
 C. After this, the 
membranes were washed six times in Tris buffered saline containing 0.05% Tween-20 before 
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and after a one hour incubation at room temperature with horseradish peroxidase-conjugated 
anti-rabbit (1: 3000) secondary antibodies directed against anti-CD97 respectively. Anti-
Cyclophilin A monoclonal antibody (1: 30000, Upstate Biotechnology was used as a control for 
protein loading. Blots were developed using Pierce Supersignal West Dura Substrate. 
Cell proliferation assay: This assay has been described on page 33.  
Invasion assay: Technique described on page 34. 
Gene Expression Profiling: The quality of total RNA sample as well as cDNA and cRNA 
synthesis products was assessed by running 1 µL of every sample in RNA 6000 Nano or DNA 
7500 LabChips on the 2100 Bioanalyzer (Agilent, Palo Alto, CA), following the manufacturer's 
protocol. Quality control criteria included cDNA and cRNA synthesis products within median 
lengths of 2.0 and 3.0 kb, respectively, and 3’/5’ ratios close to 1.00 for both housekeeping 
genes, GAPDH and β-actin [121]. The microarray reactions were performed using the Affymetrix 
GeneChip Standard protocol. The “significance-score” algorithm (S-score) developed by Dr Li 
Zhang was used to produce a score for the comparisons of the expression summaries between 
cell groups 
[122]
. The Minimum Information About a Microarray Gene Experiment guidelines 
have been met with, and the microarray raw data has been deposited with the National Center for 
Biotechnology Institute Gene Expression Omnibus (GEO), accession number GSE22578. 
Promoter analyses: The UCSC genome browser was used to and nucleotide sequences that lay 
1000 base-pairs upstream and down-stream of the start site were selected. These regions were 
entered into the MatInspector software and searched for the presence of potential binding sites 
for WT1. The following criteria were used to select sequences of interest: a. Sequences 
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belonging specifically to the WT1 matrix b. Sequences that had a matrix similarity of ≥ 0.9 and 
c. Sequences that lay on the positive strand. 
Statistical analysis: All comparisons were between two cell groups- cells treated with non-
targeting siRNA or untreated cells and cells treated with siRNA directed against WT1 or CD97. 
Each experiment was replicated at least three times. Student’s T-test (two-tailed, paired) was 
used to determine statistical significance. Error bars were calculated using standard deviation 
measurements. 
Results 
Gene Expression Profiling reveals putative target genes for WT1 in glioma cells. In order to 
ascertain the identity of the potential target genes for WT1 in the particular context of glioma 
cells, we chose to perform the gene expression profiling experiments, which have often been 
reliably used for this purpose. U251 cells were transfected with siRNA against WT1 and after 
confirming WT1 knockdown with Real Time RT-PCR, the microarray reactions were carried out 
using the standard Affymetrix GeneChip Standard protocol. Quality control assays were 
performed and RNA that met with the criteria that have been described in detail from previous 
studies in our laboratory 
[121, 123]
 was utilized for microarray analyses. Fig. 3-1 shows the 
supervised cluster analyses from three independent experiments. It is immediately evident from 
the dendrogram above the heat map that the control and scr cell groups cluster together and 
separately from cells that were treated with siWT1. To the right side of the heat map is a list of 
all the genes whose levels were found to be altered with this manipulation. WT1 (highlighted in 
yellow) appears prominently down-regulated as a result of our experimental treatment and 
speaks for successful down-regulation using siRNA knockdown. Also, there is a high level of 
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consistency in the patterns of up- or down- regulation of the selected genes, among the three 
replicates for each group of cells. Analyses of the data obtained in the 3 sets of experiments are 
summarized in Table 2, revealing a total of 27 genes that were down-regulated and 11 genes that 
were up-regulated, in response to WT1 silencing. These genes passed two separate levels of 
stringency for being declared significantly altered- the S-score which establishes significance at 
the univariate level and the Benjamini-Hochberg correction which corrects for multiple 
comparisons 
[122]
.  
The genes that were down-regulated with WT1 silencing, implying a direct correlation, 
included several molecules (identified by searching the available literature) that have either 
putative or established oncogenic roles in gliomas and/or other malignancies. These included 
INPP5A, TYMS, PDGF-D, CD97, EPAS1, FAM57A and HSPC111 (marked by asterisks and 
bold lettering, Table 2). Conversely, the genes that inversely correlated with WT1 levels 
included some prominent tumor-suppressors such as SSAT1, LZTS1, WIPI1, TIMP3, and 
DPYSL3 (marked by asterisks and bold lettering, Table3). Table 4 summarizes the information 
that is currently available regarding the role(s) played by each of these genes. 
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Fig.3-1: Supervised Cluster Analysis. Two-dimensional hierarchical clustering of samples and 
genes using Pearson (centered) correlation and average linkage. Three independent transfection 
experiments were performed for each microarray analysis. The dendrogram demonstrates that 
control and scr groups of cells cluster together and separately from the siWT1 treated cells. Each 
row in the heat map below the dendrogram shows the relative expression for that specific gene in 
the 9 individual samples (columns). The color scale at the bottom of the heat map represents the 
relative gene expression levels (0-fold to 3-fold) and the red and green areas correspond to over-
expression and under-expression, respectively. The genes that are differentially altered by 
silencing WT1 expression are listed to the left of the heat map. WT1 is highlighted in yellow to 
distinguish it from the other genes on the list.  
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Gene symbol
CD97
NDUFA1
TYMS
KRT18
UROS
SCG2
NSFL1C
LSM14A
EPAS1
WT1
ISCA1
FLJ10357
Unknown
INPP5A
PDGFD
KCTD12
Unknown
BTBD1
FAM57A
CPVL
C11orf57
DBT
NECAP1
ICK
C14orf135
RBMS1
LSM14A
LSM14A
HSPC111
MFN1
SCPEP1
TIMP3
HMOX1
WIPI1
CD55
SOX11
MAFF
DPYSL3
LZTS1
RORB
SAT1
TIMP3
CALCRL
CALCRL
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Table 2: Gene expression profiling demonstrating the fold change of genes that are significantly 
down-regulated in WT1-silenced U251MG cells. Total down-regulated genes= 27 (including 
WT1- not shown in table). Genes that have putative or established roles in suppressing cancers 
are highlighted with both asterisks (*) and green bold lettering. A total of three independent 
microarray experiments were conducted.
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Gene Title Gene 
symbol 
Fold 
change si 
Vs ctrl 
Fold change 
si Vs scr 
* intestinal cell (MAK-like) kinase ICK 0.189 0.287 
* inositol polyphosphate-5-phosphatase, 40kDa INPP5A 0.25 0.1649 
chromosome 11 open reading frame 57 C11orf57 0.25 0.25 
* thymidylate synthetase TYMS 0.26 0.287 
* platelet-derived growth factor-D PDGF-D 0.26 0.176 
LSM14A, SCD6 homolog A (S. cerevisiae) LSM14A 0.287 0.26 
NADH dehydrogenase (ubiquinone) 1 alpha 
subcomplex, 1, 7.5kDa 
NDUFA1 0.287 0.287 
dihydrolipoamide branched chain transacylase E2 DBT 0.33 0.307 
potassium channel tetramerisation domain containing 12 KCTD12 0.33 0.33 
* CD97 molecule CD97 0.33 0.307 
NECAP endocytosis associated 1 NECAP1 0.33 0.307 
BTB (POZ) domain containing 1 BTBD1 0.33 0.307 
* endothelial PAS domain protein 1 EPAS1 0.353 0.287 
hypothetical protein FLJ10357 FLJ10357 0.353 0.353 
secretogranin II (chromogranin C) SCG2 0.353 0.233 
mitofusin 1 MFN2 0.353 0.33 
carboxypeptidase, vitellogenic-like CPVL 0.353 0.3789 
LSM14A, SCD6 homolog A (S. cerevisiae) LSM14A 0.353 0.33 
chromosome 14 open reading frame 13 C14orf135 0.3789 0.3789 
uroporphyrinogen III synthase (congenital 
erythropoietic porphyria) 
UROS 0.3789 0.33 
* family with sequence similarity 57, member A FAM57A 0.3789 0.353 
serine carboxypeptidase 1 SCPEP1 0.3789 0.33 
NSFL1 (p97) cofactor (p47) NSFL1C 0.406 0.3789 
* hypothetical protein HSPC111 HSPC111 0.406 0.353 
iron-sulfur cluster assembly 1 homolog (S. cerevisiae) ISCA1 0.406 0.435 
* keratin 18 KRT18 0.406 0.3789 
RNA binding motif, single stranded interacting protein 1 RBMS1 0.406 0.353 
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Table 3: Gene expression profiling demonstrating the fold change of genes that are significantly 
up-regulated in WT1-silenced U251MG cells. Total up-regulated genes = 11. Genes that have 
putative or established roles in suppressing cancers are highlighted with both asterisks (*) and 
red bold lettering. A total of three independent microarray experiments were conducted. 
Gene title Gene 
symbol 
Fold change 
si Vs ctrl 
Fold change 
si Vs scr 
CD55 molecule, decay accelerating factor for 
complement (Cromer blood group) 
CD55 2.46 2.828 
* spermidine/spermine N1-acetyltransferase 1 SAT1 2.639 2.639 
* WD repeat domain, phosphoinositide interacting 1 WIPI1 2.639 2.828 
calcitonin receptor-like CALCRL 2.639 3.03 
calcitonin receptor-like CALCRL 2.639 2.639 
* leucine zipper, putative tumor suppressor 1 LZTS1 2.828 3.73 
* TIMP metallopeptidase inhibitor 3 (Sorsby fundus 
dystrophy, pseudoinflammatory) 
TIMP3 2.828 3.03 
heme oxygenase (decycling) 1 HMOX1 2.828 2.828 
* SRY (sex determining region Y)-box 11 SOX11 2.828 2.46 
* v-maf musculoaponeurotic fibrosarcoma oncogene 
homolog F (avian) 
MAFF 3.03 2.828 
RAR-related orphan receptor B RORB 3.24 2.828 
TIMP metallopeptidase inhibitor 3 (Sorsby fundus 
dystrophy, pseudoinflammatory) 
TIMP3 3.24 3.48 
* dihydropyrimidinase-like 3 DPYSL3 3.48 3.73 
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Table 4: Functions of candidate target genes identified using microarray. A literature search was 
conducted to determine the functions of all the genes that were revealed to be dys-regulated by 
WT1 silencing. Of the 27 down-regulated genes (green), 9 were found to possess an oncogenic 
function. Conversely, of the 11 up-regulated genes (red), 6 were found to be associated with 
tumor-suppressor activity. Corresponding references are listed in the table below in parentheses. 
Gene symbol Function(s) Reference 
ICK Promotes proliferation, G1 cell cycle progression in 
intestinal epithelial cells 
[124] 
INPP5A Potential role in promoting radio-resistance of U343-
MG cells. 
[125] 
TYMS High proliferative rate in cells; translational repression 
of p53; resistance to chemotherapeutic drugs 
[126-128] 
PDGF-D Promotes proliferation, migration, invasion, 
angiogenesis 
[129] 
CD97 Promotes cellular invasion, angiogenesis [118, 120, 130] 
EPAS1 VEGF up-regulation  angiogenesis [131] 
FAM57A Promotes proliferation of lung cancer cells [132] 
HSPC111 Estrogen and c-myc target; associated with adverse 
outcome in breast cancer cells 
[133] 
KRT18 Promotes invasion (melanoma and breast cancer) [134] 
SAT-1 Promotes cell death [135] 
WIPI-1 Involved in autophagy [136] 
LZTS1 Inhibition of cell cycle progression [137, 138] 
TIMP3 Promotes apoptosis; inhibition of invasiveness. [139-141] 
MAFF Transcriptional transactivator involved in 
transformation 
[142] 
DPYSL3 Inhibits invasiveness of prostatic carcinoma cells; 
inhibits neurite outgrowth 
[143, 144] 
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Candidate genes identified as correlating directly or indirectly with WT1 expression levels 
compared among normal human astrocytes and GBM cells. We then examined Normal 
Human Astrocytic (NHA) RNA to determine whether these candidate targets were expressed 
therein. As shown in Fig. 3-2A and corroborating evidence from previous studies, WT1 was not 
detectable in adult non-malignant human astrocytes. Our results (Fig.3-2A) also show that the 
genes that correlate directly with WT1 levels are expressed at extremely low levels or are 
undetectable in the normal adult cells. No expression could be determined for INPP5A or PDGF-
D either, and the expression levels for TYMS, CD97 and FAM57A (normalized to beta-actin) 
were 0.05, 0.075 and 0.049 (n=1), respectively. However, glioma cells U251-MG, U1242-MG 
and GBM-6 have much higher levels of all these genes. For each cell line (as for the NHA 
RNA), target gene values were normalized to the corresponding value of beta actin for that cell 
line. These normalized values in U251-MG cells (n=3) were observed to be: WT1: 0.058 (± 
0.058), INPP5A: 1.835 (± 0.488), TYMS: 1.042 (± 0.06), PDGF-D: 13.13 (± 4.187), CD97: 
0.792 (± 0.2), FAM57A: 0.577 (± 0.11). For U1242-MG cells (n=3), the normalized values were 
as follows: WT1: 0.253 (S.D.: ± 0.196), INPP5A: 1.88 (± 0.0.239), TYMS: 0.61 (± 0.96), 
PDGF-D: 0.074 (± 0.019), CD97: 0.564 (± 0.0.075). Finally, for GBM-6 cells (n=3), the 
normalized values for WT1 and candidate gene expression levels were as follows: WT1: 0.504 
(± 0.051), INPP5A: 1.12 (± 0.917), TYMS: 1.707 (± 0.284), PDGF-D: 2.808 (± 0.733), CD97: 
1.942 (± 0.946), FAM57A: 2.631 (± 1.441). The genes that correlated inversely with WT1 as per 
the microarray findings were somewhat variable in their expression patterns in the 4 different 
cell types studied (Fig. 3-2B). Only the expression of TIMP-3 was found to be high in the normal 
state and suppressed in tumor cells (0% of NHA content in U251-and U1242-MG cells, and 10% 
of NHA levels in GBM-6 cells). This is consistent with the hypothesis that in the process of 
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malignant transformation of cells, TIMP3 expression is down-regulated in association with the 
up-regulation of WT1. However, the experiment will have to be repeated multiple times to 
confirm these findings. This relation was also evident, though less dramatic, with the expression 
level of MAFF, which was decreased to roughly 77% and 85% of the NHA level in U251-MG 
and GBM-6 cells respectively, while its expression in U1242-MG cells couldn’t be determined. 
From among the other genes whose levels were inversely correlated with that of WT1 as per the 
microarray analyses, we found that WIPI was down-regulated in U251-MG cells to 48% of the 
level seen in NHA, but remarkably up-regulated in U1242-MG cells. In GBM-6 cells, expression 
of this gene could not be determined at all. 
 
 
64 
 
Fig. 3-2: Aberrant expression of candidate target genes in glioma cell lines. RNA extracted from 
NHA (n=1), and the GBM cell lines (n=3) - U251-MG, U1242-MG and GBM-6 were analyzed 
using Real Time RT-PCR for WT1 and the candidate target genes identified using the 
microarray. All values are shown after normalizing by the corresponding beta actin value. A. 
Genes that directly correlated with WT1 as per the microrarray findings. B. Genes that were 
found on gene expression profiling to correlate inversely with WT1 levels. 
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Microarray findings were validated using Real Time RT-PCR. We used qRT-PCR to 
validate our microarray findings, because it was quicker, infinitely more sensitive and would 
provide information pertaining to the gene expression levels, which is of particular interest to us 
since we are assessing the potential transcriptional targets of WT1. For our validation 
experiments, we selected from among all the targets identified by microarray, only those that had 
been implicated as having a relevant role in oncogenesis or tumor-suppression (Table 4). 
Furthermore, certain genes such as ICK, KRT18 and TIMP3 are not represented in the graph 
owing to lack of reproducible results. The 2
- ΔΔCT  
method was used to calculate fold changes in 
the expression levels of the candidate genes against beta-actin. The values thus obtained for the 
si groups of cells were then compared to the corresponding values in the scr groups of cells. 
Figure 3-3 represents a comparison of the fold change of each candidate gene obtained from the 
qRT-PCR analyses (bar graph) against the corresponding value derived from the microarray 
analyses (line-graph). We successfully substantiated the microarray results with qRT-PCR by 
showing that with both sets of genes there is a consistent trend towards down- or up-regulation of 
their expression levels. In case of the genes that were down-regulated with WT1 silencing, the 
magnitude of the fold change values using qRT-PCR (0.25-0.53 fold-change [S.D.: ± 0.04- 
±0.22]) is seen to be close to or only slightly different from the values obtained through the 
microarray experiments (0.16-0.35). With the inversely correlated genes, the fold-change values 
are much higher in the microarray results (2.6-3.7 fold differences) as compared to the qRT-PCR 
results (0.9-1.9 fold differences [S.D.: ±0.21- ±1.07]). 
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Fig. 3-3: Validation of microarray results. U251 cells were transfected with Non-targeting 
siRNA (Scr) or WT1 targeting siRNA (si). RNA samples extracted 48 hours following 
transfection were analyzed by Real Time RT-PCR; n= 3, *p≤ 0.05; **p≤ 0.01. Bar graph: Fold-
change values calculated from qRT-PCR experiments. Line-graph: Fold-change values 
calculated using microarray analyses. 
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Putative target genes identified by microarray confirmed in U1242-MG and GBM-6 cell 
lines. We subsequently investigated if these genes that were dysregulated in U251-MG cells 
were replicated in GBM cell lines- U1242-MG and GBM-6. Cells from both these cell lines were 
subjected to siRNA transfections targeting WT1 and non-targeting siRNA (scr) was used to 
generate appropriate controls. RNA samples from these groups were analyzed using qRT-PCR, 
and it was seen that from among the genes whose levels paralleled that of WT1, INPP5A, CD97, 
and TYMS were down-regulated in the si groups in both U1242-MG and GBM-6 cells as 
compared to scr groups (Fig. 3-4). In U1242-MG cells (Fig. 3-4B, n=3, *p ≤ 0.05, ** p ≤ 0.01), 
the extent of knockdown of these genes (as a percent of scr control) was as follows: INPP5A- 
65.5% (S.D.: ± 0.11), CD97- 30.6% (S.D.: ± 0.09) and TYMS- 47.7% (S.D.: ± 0.04). In GBM-6 
cells (n=3, *p ≤ 0.05, ** p ≤ 0.01), the extent of knockdown was as follows (Fig. 3-4A): 
INPP5A- 51.77% (S.D.: ± 0.26), CD97- 49.6% (S.D.: ± 0.14) and TYMS- 52.4% (S.D.: ± 0.16). 
Moreover, in GBM-6 cells, the levels of PDGF-D and FAM57A in the siWT1 treated groups of 
cells were significantly decreased to 16.2% and 44.1% of their scr counterparts respectively 
(S.D.: ± 0.06 and S.D.: ± 0.23 respectively). Likewise, in U1242-MG cells (Fig.3-4B), the level 
of EPAS1, a potent angiogenesis facilitator, was also decreased with WT1 silencing. siWT1 
treated cells had 77.5% of EPAS1 expression compared to their corresponding control values, 
although statistical significance could not be established. With the genes that were demonstrated 
to be up-regulated by the microarray analyses with WT1 silencing, we found a trend towards an 
increase in DPYSL and MAFF (GBM-6) and WIPI-1 (U1242-MG), but the high variability across 
the three independent experiments precluded the establishment of statistical significance. 
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Fig.3-4: Confirmation of altered regulation of target genes across different glioma cell lines 
transfected with siWT1. A. GBM-6 cells (n= 3, *p≤ 0.05, ** p< 0.01) B. U1242-MG cells (n= 3, 
*p≤ 0.05, ** p< 0.01). X- axis: Target genes Y-axis: Fold change in si cells (value of scr set at 
1). §§- Genes that were not found to correlate/ be expressed.A 
 
B 
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CD97 expression in glioma cells is associated with cellular invasiveness. Based on our 
microarray findings and our confirmatory findings using Real Time PCR, we conducted 
promoter analyses to look for potential binding sites in the promoter regions of the genes that 
appeared to be differentially regulated by WT1 (3-5). With the exception of PDGF-D (which had 
binding sites for Egr-1, but not specifically WT1), all the remaining candidate target genes were 
found to have at least one potential WT1 binding site. This information coupled with the finding 
of consistent CD97 down-regulation in all three GBM cell lines that had been treated with WT1 
siRNA, led us to further examine the role of CD97 in these cells with respect to its expression 
levels and consequent effects on cellular invasiveness. 
We first ascertained the expression of CD97 at the protein level using western blot 
analysis which revealed that it was expressed in all three cell lines examined (Fig. 3-6). 
Qualitatively, it appears that expression level is highest in U251-MG cells, intermediate in 
GBM-6 and least in U1242-MG cells. Subsequently, we down-regulated CD97 levels in all these 
three cell lines and noted the biological effects of this manipulation. As shown in Figure 3-7A, 
real time RT-PCR analyses showed that we were able to achieve a significant knockdown in all 
the three cell lines even at Day 4 post-transfection (n=3, *p<0.05). In U251-MG cells, there was 
a nearly 50% decrease in CD97 mRNA levels at this time point while in GBM-6, there was a 
nearly 80% decrease. In U1242-MG cells, there was a less remarkable knockdown (20% 
decrease compared to the control cells), which was nevertheless statistically significant. When 
plated on Matrigel-coated filters of transwell plates, we found that these decreases in CD97 
mRNA levels were associated with significantly lower cellular invasive capacities (Fig. 3-7B). In 
U251-MG cells treated with siRNA against CD97, the cellular invasive potential was decreased 
to roughly 53.85% of its control counterpart. In U1242-MG cells, even a modest decrease in 
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CD97 RNA levels was associated with a striking decrease in invasiveness (25.5% of control) 
while in GBM-6 cells, the 80% decrease in CD97 mRNA levels caused a nearly 50% decrease in 
invasive capacity.  
Table 5 summarizes our findings of the effect of WT1 and CD97 silencing on the levels 
of CD97 mRNA and how each correlates with changes in cell invasiveness. In the U251-MG 
cells, silencing WT1 correlated with a decrease in CD97 mRNA levels to about 52.9% of the 
level in control cells (shown in Fig. 3-3), and we have previously shown that decreasing WT1 
was associated with a decrease in cellular invasiveness in these cell lines to about 40% of the 
control cells 
[31]
. In U1242-MG and GBM-6 cells, WT1 silencing resulted in a decrease in CD97 
levels to about 69.45% (S.D.: ± 0.09) and 51% (S.D.: ± 0.14), respectively, of the level in their 
respective controls (Fig. 3-4A & B). These values correlated with a decline in the cellular 
invasive property to about 20.6% (S.D.: ± 1.12) and 5.9% (S.D.: ± 22.65) respectively in U1242-
MG and GBM-6 cells (Fig.2-2B). CD97 silencing in U251-MG, U1242-MG and GBM-6 cells 
(Fig.3-7) resulted in a decrease in cell invasiveness to 53.85% (S.D.: ± 14.64), 25.5% (S.D.: ± 
21.38) and 49.82% (S.D.: ± 11.71), respectively. Thus, it is clear that the expression of CD97 in 
glioma cells is of great functional significance. We also examined the effects (if any) of 
knocking down CD97 on cellular proliferation, even though such a role has not frequently been 
attributed to this molecule. Our findings showed that there were no significant differences 
between the proliferative rates of the control versus experimental groups across all the three cell 
lines (data not shown). 
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Fig.3-5: Promoter analyses of candidate target genes selected on the basis of their putative roles 
as oncogenes or tumor-suppressors. The UCSC genome browser was used to search for promoter 
sequences for each gene using the search criteria of 1000 base-pairs upstream and downstream of 
the start site. Sequences were then entered into the MatInspector software, and a search was 
conducted for potential binding sites specifically for the WT1 matrix within the Egr-1 family of 
transcription factors. From the results generated, sequences that fulfilled the following criteria 
were selected- a) members of the WT1 matrix, b) matrix similarity of ≥ 0.9 and c) sequences that 
were on the positive strand. Sequences with green numbering belong to genes that are down-
regulated with WT1 silencing, while those with red numbering are for genes that correlate 
inversely with WT1 levels. The underlined areas represent the potential binding sites. The 4-
capitalised nucleotide sequences represent the core- The "core sequence" of a matrix is defined 
as the (usually 4) highest conserved positions of the matrix. The maximum core similarity of 1.0 
is only reached when the highest conserved bases of a matrix match exactly in the sequence. 
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Fig.3-6:  Western Blot showing CD97 protein expression (≈92 kDA) in U251-MG, U1242-MG 
and GBM-6 glioma cells. Cell lysates were prepared using 1% SDS-lysis buffer. 10 µg protein 
was loaded in each lane. Rabbit polyclonal Ab (Abcam) was used to detect CD97 (1: 200). 
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Fig.3-7: CD97 silencing suppresses cellular invasiveness in glioma cells. A. Using siRNA 
directed against the CD97 receptor, we confirmed a significant knockdown in CD97 RNA in the 
tumor cells on day 4 post-transfection by Real Time RT-PCR in U251-MG, U1242-MG and 
GBM-6 cells (n=3, *p<0.05). B. Treatment of U251-MG, U1242-MG and GBM-6 cells with 
siRNA against CD97 resulted in a significant decrease in their ability to invade through the 
Matrigel-coated filters of transwell plates, as compared to cells that were treated with non-
targeting siRNA (n=3; RLU= Relative luminescence units). We confirmed that the decreased 
expression of CD97 did not result in decreased proliferation rates across the three cell lines. 
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Table 5: Effect of WT1 and CD97 silencing on CD97 mRNA levels- Correlating these results 
with changes in cellular invasiveness. 
Cell Line Following transfection with 
siWT1 
CD97 mRNA level                  Cell invasiveness 
(% control)                               (% control) 
Following transfection with 
siCD97 
CD97 mRNA level           Cell invasiveness 
(% control)                     (% control) 
U251-MG 52.9% 40% [31] 49.16% 53.8% 
GBM-6 51% 5.9% 20.87% 49.82% 
U1242-MG 69.45% 20.6% 80.42% 25.5% 
 
Discussion 
 
We have identified, using gene expression profiling, some of the genes that correlate 
directly or inversely with WT1 levels in the specific context of astrocytomas. Of the 27 genes 
whose expression patterns mirrored that of WT1, 7 candidates were selected for having 
established or putative oncogenic functions, based on published literature. Conversely, of the 11 
genes whose levels were up-regulated with WT1 silencing, 5 had been implicated in the 
suppression of tumorigenesis in some way. We have validated the microarray findings for these 
genes in U251-MG cells with Real Time RT-PCR and have also confirmed these expression 
patterns in two other GBM cell lines. We have also demonstrated here that most of the genes that 
correlate directly with WT1 levels are not expressed in normal human astrocytes, but are highly 
expressed in GBM cells. This observation strongly implicates these genes in the process of 
malignant transformation, necessitating further investigations into their precise contributions to 
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this process. Our promoter studies revealed potential binding sites for WT1 in the promoter 
regions of all but one of the putative target genes. In the lone exception- PDGF-D- the promoter 
region did however show potential binding sites for the Egr-1 family of transcription factors. It 
has been established in previous studies 
[36, 43, 44]
 that WT1 shares the consensus sequences 
recognized and bound by the Egr-1 family of proteins. CD97 was uniformly down-regulated in 
all three cell lines with WT1 silencing and displayed sites on its promoter that could be 
theoretically bound by WT1. Moreover, it has been well established as a facilitator of tumor cell 
invasiveness in other malignancies. Given these considerations, we chose to further examine the 
role of this protein in gliomas. This novel undertaking revealed that in glioma cells, as in 
gastrointestinal malignancies and fibrosarcoma cell line HT-1080 
[119]
, the CD97 receptor 
appears to foster cellular invasiveness, and decreasing its endogenous expression caused 
significant and striking decreases in the ability of the cells to invade through Matrigel.  
The complexity of the WT1 protein has for long posed a formidable challenge to those 
that have ventured to study its varied functions. Its vastly differing roles in different cell types 
make it difficult to categorize this protein as a tumor-suppressor or an oncogene. In certain cells 
like the progenitor cells of the kidney, WT1 facilitates their exit from the cell cycle with 
subsequent differentiation 
[87]
. In the neural and vascular progenitor cells however, it has the 
exact opposite effect- facilitating proliferation and preventing differentiation 
[87]
. Hence, any 
conclusions about its role(s) must be made strictly in the context of the cell-type examined. This 
was the basis for our decision to choose the microarray technique to study differences in gene 
expression arising out of manipulating the levels of WT1 in cells that expressed it endogenously. 
Moreover, silencing the endogenous expression of the protein to look for the resultant 
differences was a more appropriate model rather than over-expressing WT1 in a WT1 null cell 
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line, due to the myriad variables (WT1 isoforms, concentrations etc) associated with the latter 
technique; the former method was therefore selected in order to more faithfully assess the 
possible functions of WT1.  
Identifying the target genes via which WT1 might influence its role in the neoplastic 
transformation of glial cells was of paramount importance for many reasons. First, as a regulator 
of transcriptional and post-transcriptional processes, WT1 has the ability to co-ordinate all the 
key aspects of glioma biology- proliferation, invasiveness and angiogenesis, by regulating the 
expression of the molecules that mediate any or all of these processes. Moreover, given the rapid 
progress that is currently being made in the field of immunologically targeting WT1, it is evident 
that WT1 is a force to be reckoned with in gliomas, and our findings also help to fill in the 
missing links in understanding how it functions. Finally, knowing the identity of its associates 
can help in devising therapeutic strategies that target one or more of these components. Since 
these components belong to different intracellular signalling pathways, targeting them ensemble 
would shut down any possible “escape routes” that malignant cells are notorious for taking.  
The identification of at least 7 candidate oncogenes that were suppressed and 5 putative 
tumor-suppressors that were up-regulated by WT1 silencing confirmed our hypothesis that in 
gliomas, WT1 has more of an oncogenic function. What was more interesting was that among 
the genes that varied directly with WT1 levels, only TYMS, CD97 and FAM57A were expressed 
in normal human astrocytic RNA and even then, their expressions were in the order of a 100ths 
of a fraction. These same genes were expressed between 10-100 times or more in untreated GBM 
cells, thus making a powerful argument in favor of their roles in promoting malignant 
transformation. 
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Our study has also revealed a novel protein- CD97- that is aberrantly over-expressed in 
GBM cells. This protein has well-documented roles in mediating tumor cell invasion and even 
angiogenesis 
[118, 120, 130]
. In various gastrointestinal malignancies, an increased expression of 
CD97 has been demonstrated at the invading front of the tumor 
[145, 146]
. Likewise, we have 
shown here that in glial neoplastic cells, too, it has a significant role in conferring invasiveness 
upon the cells. From our findings, it appears that in U1242-MG cells the extent to which WT1 
decreases cellular invasiveness can be roughly accounted for by CD97 alone. In U251-MG and 
GBM-6 cells, on the other hand, WT1 silencing causes a much more pronounced decrease in 
cellular invasiveness than that seen with CD97 silencing alone. In both these cell lines, PDGF-D 
was also seen to be significantly decreased with lowered expression of WT1. It is well 
established that PDGF-D is a strong mitogenic and chemo-attractant molecule and it can initiate 
several malignant features like proliferation, invasion and angiogenesis in brain tumors 
(reviewed in Ref 129). Examining in more detail the relationship of this growth factor to WT1 
undoubtedly merits further attention. 
  Although our promoter studies suggest putative binding sites for WT1 on the CD97 
promoter, definitive evidence is still required, preferably using the Chromatin 
Immunoprecipitation (ChIP) Assay or even Luciferase Reporter assay techniques. For the 
former, a reliable antibody to immunoprecipitate WT1 is essential, and has been a confounding 
factor in our attempts to study this.  
  The ability to localize the invading neoplastic cells in situ has for a long time been a 
challenge in the treatment of brain tumors. With the identification of CD97 expression and 
function in glioma cells, determining its ability to serve as a reliable marker of invasiveness 
using immunohistochemical staining of glioma tumor specimens opens up a potentially 
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interesting line of investigation. Another option would be to devise a therapeutic strategy aimed 
at targeting the CD97 receptor, which would be relatively safe, since it is virtually absent in the 
normal human astrocytes. Further investigations are also necessary to determine the effect of 
targeting the CD97 receptor on angiogenesis, as it is also known to affect this process.  
Our study thus opens up entirely new avenues in the field of glioma biology. Hitherto 
unknown targets have been uncovered, and more in-depth analyses of these molecules should 
hopefully take us several steps further in our attempts to conquer the fatal disease that constitutes 
GBM. 
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Chapter 4: General discussion and future directions. 
 
In the preceding chapters, we have shown that the developmental regulator Wilms’ 
Tumor-1 (WT1) has a significant contribution to the invasive property that typifies tumor cells in 
malignant gliomas. WT1 was also shown to promote tumor cell growth in vitro and in vivo, by 
studies in our laboratory and others 
[28, 30-32]
. Given its zinc-finger transcription status, we 
embarked on a mission to uncover the target genes via which these effects are mediated. 
Previously established pro-invasive target gene candidates such as PDGF-A 
[88, 89]
, Snail-1 
[86]
 
and E-cadherin 
[86]
 failed to demonstrate a consistent correlation with WT1 expression levels. 
Expression levels of the tyrosine-kinase receptor IGF-1R were analyzed in relation to WT1, to 
account for differences in proliferative rates between cells that had WT1 expression versus those 
in which endogenous WT1 expression was abolished or increased. Our hypothesis was that IGF-
1R, when up-regulated, might mediate a non-apoptotic form of cell death called paraptosis 
[101, 
106]
. We observed consistent up-regulation of IGF-1R with WT1 silencing in U251-MG and T-
98G cells 
[31]
, and a down-regulation of IGF-1R protein and RNA upon over-expressing the WT1 
(+/+) isoform in U251-MG cells. However, siRNA-mediated silencing of IGF-1R in U251-MG 
cells was associated with a decrease in cell proliferation, thereby indicating that the IGF-1R up-
regulation consequent to WT1 silencing was more likely due to activation of an alternate survival 
pathway by the tumor cells, rather than the mechanism by which WT1-mediated cell-death. 
These findings support the theory that the transcriptional targets for WT1 vary depending upon 
the cell type and differentiation status, the isoforms of WT1 present in the cells under 
investigation, and the level of WT1 expression. Hence, in order to ascertain potential targets for 
WT1 in gliomas, we chose to evaluate changes in global gene expression levels following 
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suppression of endogenous WT1, using microarray analyses. Our results from three independent 
microarray experiments revealed the identities of some candidate target genes that were 
consistently down- or up-regulated with WT1 silencing, implying a direct or indirect correlation 
respectively, with this protein. Based on literature search results, the altered regulation of these 
genes, we observed, could not only explain WT1’s effects on proliferation and invasion, but also 
uncovered a potential role in angiogenesis (Fig.4-1).  
Fig.4-1: WT1 regulates different aspects of the malignant phenotype that characterizes glioma 
cells- cell proliferation, invasion and angiogenesis. The potential target genes that enable it to 
effect these processes (+), or those that inhibit the process (-) and correlate inversely with WT1 
levels are also listed. Genes highlighted in bold are those that are common among three different 
glioma cell lines examined. 
 
 
 
 
84 
 
 
An involvement in angiogenesis will not be surprising given that the fatality in WT1 null 
mice is a consequence of severe cardiovascular abnormalities 
[84]
. Moreover, in glioma tumor 
specimens, WT1 expression has been discovered in the endothelial cells of tumor vessels 
[85]
, and 
while it has also been shown to regulate the expression of pro-angiogenic molecules like Ets-1 
[85]
 in tumors, its own transcription is potentially activated by hypoxia-inducible factor-1 (HIF-1) 
with oxygen restriction 
[84]
. WT1 is thus well-linked to the process of blood vessel formation and 
it would be interesting to study if the expression in vascular endothelial cells in tumors is a 
coincidental finding, or if it actually contributes to the process. Our laboratory has established an 
in vitro 3-dimensional model to study angiogenesis, 
[147]
 which would well serve this purpose. 
Further, this model could also be used to ascertain which of the pro-angiogenic target genes 
identified- CD97, PDGF-D and EPAS1- contribute to this process in glioma cells. 
Based on our findings, it is evident that WT1 regulates the invasiveness of glial 
neoplastic cells, possibly via altering the expression of CD97. While definitive evidence for 
CD97 regulation by WT1 would only be obtained by demonstrating binding of the latter to the 
CD97 promoter, there is substantial proof to validate this hypothesis. For one, the expression 
patterns of both WT1 and CD97 are closely related across all the cell lines studied- both proteins 
are expressed at much higher levels in GBM cells as opposed to normal human astrocytes and 
suppressing the endogenous expression of WT1 significantly and consistently down-regulates 
CD97 expression. Further, both proteins notably affect the invasiveness of the neoplastic cells. In 
U251-MG and GBM-6 cells, down-regulating WT1 has a much greater impact on decreasing 
cellular invasiveness than that seen with CD97 suppression alone, and pro-invasive molecules 
like PDGF-D could be additionally implicated. In the highly invasive GBM cell line- U1242-
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MG, however, even a modest decrease in CD97 level dramatically impairs the cells’ ability to 
invade. The absence of significant dysregulation of Snai1, E-cadherin, PDGF-D, KRT18 or 
DPYSL3 in these cells gives rise to the hypothesis that U1242-MG cells are heavily dependent on 
the CD97 receptor expression levels to retain their invasiveness. 
Invasion of the neoplastic cells into surrounding normal brain parenchyma involves inter-
cellular interactions and interactions occurring between tumor cells and the surrounding 
extracellular matrix, facilitated by adhesion molecules, chemo-attractants, and perhaps most 
importantly- by matrix proteases produced by tumor cells 
[148]
. In vivo assays and organotypic 
brain slice models are considered superior to in vitro assays for invasion, since they provide an 
environment that facilitates this study of how the invading neoplastic cells interact with the 
unique extracellular matrix in the brain. However, a key element in promoting cellular 
invasiveness is the inherent motility acquired by malignant cells 
[148]
, which is a property that can 
be examined in great detail using an in vitro invasion assay. In this system, it is also possible to 
determine and manipulate the properties that confer this enhanced motility upon the transformed 
cell. In our case, for example, manipulating the expression level of WT1 or CD97 generates an 
excellent system by which to study the exact contribution(s) of these proteins to cellular 
invasion.  
The microarray analyses identified several pro-proliferative proteins that varied directly 
with WT1 levels, such as ICK, TYMS, PDGF-D and FAM57A, and several pro-apoptotic 
molecules that varied inversely, like SAT-1, LZTS-1 and TIMP-3. WIPI-1 which also inversely 
correlated with WT1 plays a role in autophagy 
[136]
- a non-apoptotic form of cell death. It is 
interesting to note that among the putative oncogenic targets, only PDGF-D has been studied for 
its contribution to gliomagenesis. Information pertaining to the other molecules is mostly from 
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studies conducted in gastrointestinal carcinomas or lung malignancies 
[118, 120, 124, 126-133]
. Thus, 
the aberrant dysregulation of several genes with hitherto unknown functions in gliomas has been 
presented for the first time in these studies. 
Future directions 
We have validated the microarray findings at the mRNA level for all the candidate genes 
in three different cell lines. It is important to demonstrate that these genes are similarly expressed 
at the protein level, as well, using western blotting, in order to rule out any post-transcriptional 
regulatory differences. Further analyzing the exact role and contributions of each protein to 
glioma is beyond the scope of this study. However, such investigations would undoubtedly 
broaden our current understanding of this disease. 
Our findings from the in vitro invasion assays following WT1 and CD97 suppression can 
be supplemented by orthotopically implanting cells in which WT1 has been silenced, and 
detecting changes in CD97 expression at the invasion front, using immunohistochemistry. 
Further, the invasive patterns of the tumor cells can be visualized histologically or using MRI. 
Brain slice models can be similarly utilized in place of or in addition to the above-mentioned 
system. The U1242-MG xenograft model has been established to closely mimic the key features 
seen in GBM with features of extensive infiltration into the brain parenchyma, perivascular and 
subpial spread of cells, microvascular proliferation with typical neovascularization and even 
necrosis 
[99]
. Moreover, based on our findings from in vitro experiments this cell line 
demonstrates a high sensitivity to CD97 expression levels. Thus, it would serve as a good model 
to test our findings using these experimental model systems. 
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Finally, demonstration of WT1 binding to CD97 promoter using chromatin 
immunoprecipitation assay or luciferase reporter assay is also vital to confirm transcriptional 
regulation of the latter protein by WT1. 
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